var title_f26_54_27488="MR image appendicitis in pregnancy";
var content_f26_54_27488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of appendicitis in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 391px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGHAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBfiWDBp/zHKn0rwudsStjkE1738UIc6YST07V4LMBvbHNADgoSMn1rMuNwkJ45rQzmM561S8ti5LGgDb8IpvvFAB3Vq67bhbs8HNVvBCMNWj4710HjZFivh5Y+Y9aAOPlCq2T1qNkJG7IqadG3hnHNIId/JOPagCuHPROtROnPJ+appE8puOc1Gq4bOcmgCB0ycU5YipBB4pXJ8znpUh+dflPSgBsnIGKLW1mnnCR85p0SeZ8gODXaeEPDVzN+/jPTmgDiNd024siC8bc98VjMFxk9e9ew+JNN1C4g8qS0ZlA+9iuBvNBeAklTmgDmo4I5XHUGtFdORU3PnHrV600WSWUblKj1q1q2n3ccGxUOwDrQBzE7xKxXsKqSFCeTxUtxZTEkFDn1qKHS7qVwChxQAsEXnMADxWtBYxqAScUtnpUkA3NkGmXSspxnBoAuu0UceIuaokjk0DKRYHU02NdqMX70AZl0+WaqB5NXrrA3VQoAKdxt96TPFFAEkBIkXFb6qTANtYMPzONoxiun09BJb4PWgDnr6NxJkjIqvGuWwK2NRhaMmstgyjKjBoAjCZkI9K2dJbYxFY8Z+Y5+9Wtpx+YZGDQBamkDOc1WMgJIAqxdAbhioH2pjigBTjHNLhcfMeKieQcEciomkyetAGhC0a/LmnSMI24qhDjdnNTSndjNAF+Gb5hkdatOufm61lwueAatpK2QFOTQA/IY7SDUfl7WOKe0uG2kc+tDEEYVvmoAgkQ7TgZrOuMhSMVrwkoSrcg1XvIQ4OygDFZjtPIqu8uRgVYlt23EZxUIgOeTQBEoy1WlUgClihG4AVeEWBjFAH1N8XYhDpBc8E8Yr57VNzOTX0P8b7iNtNCMMdxXzurkFlNAEU2NuOhqvG4LYbrT5lPOfwqvGNrZbrQB23gCAz61Eucc10XxAtfI1AevrWD8NEY61CR1zXdfE+yOI5SMZFAHl0hZnwRmqxDGbAPFaZtCAChBzUE1sYDkEFjQBRmjdpAAMiq7sFk24rTRygII5NVplUt93mgCB/LIy3FREqPunipTGD9+oJoi3KcUAbXhqztZr1Gu5hHHnk5r1q21XQrO2WGyvBkD1718/wB4J1T5XKn0BqpGt+OUaQmgD6Kl8WKEMKxpJGeC+axJr/T5GfzY1O7vXlml3eoQrsfcc+tb1pcsvEoPPWgDpk+zSOdqhU9asu8H2VkdQwxxmsqwijuRjzAv41KURGMauGI96AMu8t7cqzeUoPashrxLUEmJc/SulmjEp2sAMVz2twbeFXNAGTe6p5qfKuD6CsmR/MOWPNWp4lTnHNVWhCsHJoAY+5sBaJlYx4PBqdIvMZSvFLqACIB7UAYU5yCD2qmeR06Vcuzj7v41VRd7UAMpRjPNOAy2D0FJjmgCeEhAPeuj0xsQ81gW67l5HFaumyFW2t92gC1qcRMRcVz7BxkkcV2A2SwlWrD1O38kH0oAw0OWJ71qaazM+1hiqIjUNmr9p8rAigC/cgRnB5JqlIueD3q867hluTVS4XjjrQBTmPlAgciooXDHJpzB93PSoWRi/wAg4oAuxuu6pWYZ56VWXgcjmpVJY/PwKALkGGIBPFaa+RGvBy9YsfD5B+WrsKh/mBJxQBO9u8hLLVKaCVGyDWtHv2fLUU0EjrmgCnbtx85qTAf5UPNRzwOFJXtTbdJCuQDkUAJNbDPzHmq32Ms3GaunMh+bqKerKBx1oAgSxCKCDk0EYOKsIhck5xTTEc0AfRXxunSWxUEYbtXgIDYbNe6fHd0Mcarw2OleGKzEgHpQA3b+7O889qghjyxJqzcLjGaS1iMswVeBQB3HwxYJrcPGTnpXqHxTty2lpKy9v6V5b4DhktvEMGOSGr2/x7ZyXXh7ey4CrnH4UAfPY3wgsp4qIMxyzHOatSBzMyKnANQzAIuQOaAKuMPk96jmwvLDk9KtwKHO9+gqG6kj35I57CgDOfg5b8qimnKDKrzV94AV82b5V7VnvcRb8YGB0oAuaPpMmpXKl2A9q77TNAhsZY/tEG4H2rE8JSW0LrNK+COi1tazrlxc3Ci1jJUcDFAHVJ4ZsHXzxGOn3cCuO1zT4ku2WBcc9K6jwzrb2hBvlLZH3TU95awalqqzWqj5jyo7UAeayQSWrEh8Z7VS+1tbT79+6vQfHHhv7NbCWBiWI5HpXls0LQudxyc0AdTaXsdxgk4NXPsAuDg4KnvXJ6Uc3ChjgV26h2hVYMketAHKa5pX2WQ7RuHrWDJbqjHPJr1JdKa6h+bk+9ZNzoNush7t6UAcbY2oYlmGFFY2uMpmIT7or0240yG1sXJAyRXlmuFVuHC+tAGROSSAn400Ls5FJlgSR0pwcIuW6+lAEecPuYcelSKoZgSPlqHfubnpUsRIcA/dNAGjaxj04q1s4+UYqKBWVQV6VoxFHjweDQAtlMGG1jzTdRh8xDlgQKpSqysdnBqDzJyCHJoAqtCd5Hap7NSJADTCWwaktmH40AaaqwPHSq19kduavWyFkBB5pmoxsI8leaAMSUEimAEEEdKndc05YSD7UAIoU84p5+cgYwKf5Y3DbQw5wDQAips4Per+njYCcZBqoib2ABya14ohDCC3WgC1bFApLECpWZQpOQVqiu1lOTihRt+82VoAbKyknA4pkdwq5CjrT3UY9jVRoysoKfdoAey5fcOKQJubgVI67gADUTTGFsAZoAkKMWAXgVMAAMHmqy32Thlx70/7RH60Ae5fHpGaaJ+nFeKYdSCRxXs3xyuvPvI4+yrmvG3LOwA6CgCO7YnFT6ZKBIM9ap3kmCMdqWwYmbd1oA9E8AA3HiSA56NnFfRPiSze98PuqjBCdPwrwD4TWxuPE0JHQGvqhrON7VY2HUUAfIuqRS2N5KpUZBxzWPNHI4MjYGa9j+J/gK8E73WnJvB5KgV5PPpt8rNHcKUx1zQBnwswBUDNXbW40uyUzajy4HC1i6lqaaYpRCGfuRXHXuoPeTZkY4oA6HxBr66jOVt1CRDoBVG3V5SABmsyEqTjFdF4ZnibU4opl/dk4JoA6/wh4Xvr/EoRvKHfFdtJpq6aAdqsRwRTr3Ur7RLSGLR4d8Eg5YLmrOk2GpXkRub8EKwzzQBPbxWktoWCg3BHArb8OWiaVBJPdjLv90elZ+lpaaeXeQbnPQ05NXfzz9rXdBnjHagDTkto7oSyTncj5wDXjvjXQXsdRaSMZiY5Ferz3Sna8DZj9M1xPxGuxLGqwenNAHCQBIpFyPyrttKlCQqQPlI71yGmQ+Y4Mwru9HtVkUIVwlAFyA7UZom4IqtAyGZt6kufarF7bmBCIzgVLpsQaAuVyw6mgDL8SQrFprPg8ivFNbVWnbHrXtPjO8B0h1VcMO9eGX0jGZyfWgCm3HymoGQb+TxU8mHALcYpjBcbhzigCBlKtUsKnduamlweTwafCD1JoA17Vm25FXo1WVeuGrKiO1chh9KtRszAbT81AFw7YWHm/nVW6ePOV6VYyJI/Lm6+tVZYViUgnIoApTNuPHSoY3G/jrSsuXOD8tMijKvmgDoNLcnBarl629egxVLS1Bq/LERy3SgDBuEwcqKI2+XJrUaBXyTVF4lViBQA5URgCrc1ILPziNh+tQ+SFHynk05JHgBCnrQBaIt7VcBsyVWnvTJxkVnXWS5YtzVN2YnKvigDXa72jk8ip0u1mTrhq50TMG+Y5qeK4BYAZBoA6FZdwwxqUKdvFZ9m4cfN1q4jvyB0oAZJuQ5qnLIWarbeZISCDiq08RTqDigCCQtmnKDik6nIPFBkoA9r+Nd2kmrr5Z42ivMFkweK9F+MKRf2uCh/hFeaOQOBQBXuTulyKlsg4kBTkelV7j5z8vWrFmXQDb1oA9t+CFoJdVExGGWvp9okFkGAy+K+fv2frQsDPIOtfSPyRWu4jIx0oA5bVZ1t7OQyLvOPSvlL4v66U1KaK1G05IOK+nvGGv2GmWUxuioJBwDXyR46ubW/1eedCNrMSPzoA82naWZy0hJY1LY2AuZQMYPrWo0cQJwKmsXVZQqjHvQBd0/w+ryKpxj1rp9O0LT7O4V7lhsHessSSRWxaM575rLOsvLIYpScCgD3zR9bsf7PFvbIspxha3dH0/UtQgMMqFEY/L9K8K8L6obS7RyfkU17h4L8cG8uktnj2gAbWoA9F0XwdpdlopTUgjTsD8zEZzXiviaT+zNckskTzYXPyn0r0HxXqd4zBVc4PQ1wGt376RE1zc2/nyn7pIzQBr6ZbWdvADdyqm4ZwTXnfxBlthff6KwZPasDWPEV5q1wZJN8IB4UDArNlnNwFUuS/vQBu6NEJmVtvy966yGXYVSIfL61T8K2yrpuWXnHpWgzKiERrn1oAJRJPMiHO0nGa22tEt7VY0bG7qaxtInL3JWQcCnavesLpY92I/WgDD8fp9n04IOcjrXiF626UgV7D4+nZrNAp3JjrXj1/jLbKAKLuC21hgUjj5PkPAqMNwQw/GkUnt0oAdGAx+c07JR+OVphKscnikViPfFAF6MgDk81dtM5zms6HEnJ4rRiB2YHSgCxv2vl+ahncPknpTwmEJbmqUxyTg0ARlhuPPFCElsdqgON2DU0RywAoA6LTF8uLcwqwZGlbnpUdiytb7T6VA11sm2Y4oAku22gBeKz2OT6mrF1LgZI61WiZVO5qAHdOe9Mdt33fxp+dxzTWAXkdaAKdwuc1nPHh+uBW4Y8x+9Z08QBOaAKDLg8HIqRMZG0c+tMYbSQOlSQoxYY6UAaVkxLCtlSQoIGRVGwh6DH41sxW5HHagCAS7hwtOO2dSrripJYtn3RUIkZOq0AVprNFBwcVmumGOK3MrIpDcVUa0BY4PFAHovxSjYa2wLZXaK8/nUDiu6+KE5fWG552ivP53J4oAg8wh8Yq/ZMWkXI71R3hOCMk1e0/Mk6ADjIoA+nvgZHss0OOP8A61e4aldBLTK4xivKPgrZhNIgD9x1r1PU7UNFszgYoA+Yvjlrcr3XkoSAK8ZAkmBMgJHrXrHxzRINXKj0ryd75Uj2DpQBAIkUnJ4pIWQSbUxz3qpLcB3wOlWbWDK7o2zQBrSzfZ7bYp3ZFYZQvPlRzmug0W1huJgtzIAvfNXdb0mCFg9i4ZR6UAUtPZt0ccqkD1xXtfgK3gNqmV57PXiyXm6Hy3X5l6Gum8DeL5NPnNtd58g8AntQB7XqNlf3TAWmJMdMc1ah0uSGENrNuHUdiuam+FN+Z78yGQSQseB6V1/xN3x6YZLdhux90d6APKtZ0vw1qdyIxb+T2JAxXnHjfwvaaJepNYvvhb36V6jpS2WoWWy+j8uYnGTWb8QvDtvZ+HTPG+8fWgDl/Dd/FDahtu5CORU88geVpYB8jdQa5zw/cIluY+pPatSXzYV3cqpoAmtZzE7vjFY2q3rSOew7Vca4AU5HNZl78wO4YNAGRrsxew2s2RivOb7G4hema7/V0/0Vt/4VwV6uGbAoAznKqQMUx1wd36U8KCCWGTTc5+Z+3QUAMxnlulPjUdR0pM71JPTtTkII5OMUAXbG23Pk9K2o4flxt4qjpLI2AxFb7MvlhY1zQBmTRAIcA1j3K4JxW/qcyrDhUwa5yeQE88UARDBGG61NEF3LiqpIMmO1W7MASjjigDpYI0jtFcHrUIhUvv7UzzcIE/hqQLiLCmgAltgw3dVqkY1DH0rYt1AtmDH8Kia3UxMQOaAMhs7sjpTWR2GandCCR0qIsy8E0AJlkX1qpcctk1YZiByagYEnNAFVwPSrFlaM0gIPy+9TJDu5YYFRXU7Rrth4oA3kEcMXysN1Qm9kTvxXMm5m35LEVOly7YGc0AdFHfbhz1qRZt/JFYsDk1rWQG3L0AWNysOBijyxTG3fwilDnHI5oA7P4pNG2tEpx8o4rgp8beBXX/EKZZdTL/xYFccJCWww4oAhCj6muj8MWZnvIUA6sKybS0aSXIGVrq/Btu51mGNOu4UAfW3wysY7fRbeNuCEHP4V1OsxPFbM4YkAVi+AoWh0+Lzum0dfpXT6gF+yOW5XHSgD43+ODSz607HOBXkzQeavyHmvZfjshTVnaMfKa8aCtGxbODQBPBo8uPMYfJWnbLBbxEq2T3FULbVp4/3HVWqVwqqc53GgB32hEYvuIFTjUh5JCudtVYYYHU+dkd6p3AiV8R52igC6kxY7lGasRxu7B2GBSacY9uQvArf02x+2tlR8voKANjwb4nvvD10kkcjND3WvXdI8Sf8ACUXcbTXRSIdUJAryq18PvGwaRCYzWhN4bk8sPpk7xv6ZxQB6f4gvtD0y5j864QEc8EVxPjXxbaahB9ntZd0GOlcbeeEdWuMtdyOW7ZNZ8Xhm7RtrFsUAWdJnhF+AnTNdfqFpJeRK6cKorm7LRngkUhSWHXiuxVitoEOc45oA465nMc4iI5Bqhq1yxuI0UYNauqKqXJYDJrBnmzfDIyM0AR+ISZLREAw2Oa8/1AlG2Y5r0XVmEmNorg9Yj2zmgDHOM1G0ZY+1WGT5qCh/hoAquhxhaYIm6Grargk96RVLNx1oA0NKgTaAWIatcia3GVUsvrUGiWSzfeO1hXRI0SW7xMASO5oA47Ub1pTgpisieRT0rU1Zw0zKoGAax5ME4UdKABAZDxxitDT1PnAHkVQV8AbR9a2tJUONxoAtTHLhQOKmQ7cCo5GzLlRwKnVlf60ASRhjyTxUqTgAhhxUsMPmR5HanCEN95eBQBUeAXJOzioG0pnP3q1/KTjZ8tO2RxkO0mB9aAMR9KfI3Gia3jt0+bqK07u5imYbHAI96wtWnDcA8igCncXJBO3haoyzK3I61HK5YkGoR70APfLDJFImQeDTSSacik8igDW0396wA61spEQQCcCsrTFK4bHNTX2oPHxigDWVTkBWzTije1ch9unVyyuefepf7Wuv71AHaeIZzdXxc88ViyM2QNtXNQmxNnFVo5N7dKAOq0OBHsHbA312Pwz0Ge81pJQMKjZNcPpszR2pI4FesfBK7lm1Apt+XPJoA+j/AA9AEtEjYcAVf1BQlsQo68YpNMwtuNoy2OakuZkVD5q/NigD5a+PlmUmEwHBzXg5AlJBOGFfT/xzszPbNLt+QZr5ku0EdyxH3c0AJb237wNkEitu6SCS3Qxj94BzVC2TzQNhx71ftdOlmfERJNAFB4/MXO05FVpETcCUOa35VFkhSRA0lNsI4rmXmLLelAGXaSMXVVjIFeg+D49k6FlyvcVzbReXcqFiwQelekeELIXUQMcf7zpQB1lp9hyplKgf3TUGo28EkgfT1y46YrI17w3qKRtcQOc4+7mucsdV1XRpC7wM31FAHUyXN1ETHqFuwHZscU9EtvLzKVwafpnj2x1W0a01O0Ec54ViK57U7lLBmSc5jY5U+lAGtdIlvbtLAAcjisC11rbM6XUZKnvSy3s8un7LUFh2rPiuR5JS7g/e9iaAItWkV7omEfKa5i9dre9AI4JrflnXzNoFY+sbZZQQOlAD7lg8a7e4rk9agO88VtTXTMUVRgCs/VnMkfTtQBy7ryaZkgfL2qWbAYmqxfk4oAc3zdOtSQRFnAXrVaN9xPY1f0xWaSgDqNItxtUPwfWk127hgjMcJ+b1pILgQwnzDjiuY1K7DztnpnrQBUuJCxZmPWqaNtJI60srFm65FMFAD0zvya6LS4/3RY8VziE7xmumsci3yfSgB7OoyB1qzp8RdsMDzVHOXya2LJtsW4DNAFriEBV/KiSQhc44psZEmWPWobqfYCp6UANlmyhbOMVg6lfO+VViBU15ckEjPFY9y4Lcc0AQrPIH3FjT5HeQbs1WBy3zdKmRy/A4FAED53Hd1ptSSKQx5zTFxnmgAFXLOLkEdaht13PnHFb1lbRqA/f0oAktx5cRLDBrH1GRmc46V08sAaDPrWBf2EyjI5FAGP260Ae9TG3IHPWgQe9AHZahaTJMVlRgMelV7GAtcbOeuK9z8WeHLSUNKVWOMDrivNrm3sbOZijAkdDQBZW2t4tOKucSEV2nwP1BLfWzb5Hz9DXm010JQQTx2rb+HMzWPiGCTfj5hzmgD7X0yZUhVRy5ApNQdiu1wMnvWHouo+baRbeWIHP4Vo380piAPPvQBxPj61juNIuI50yhU818h+JLZYNTlji5Tca+zPEzLcaRNGcfdNfI/jSJLbVpgOm4/wA6AMuyj8uIYzg1v2V3BaWzbW/eEVi290vkYAyKhWEyS7skKe1AFs3O64aSX5s+tafhrUIU1HCxBifUV6C2k6b8SNCWTRLa10/xjYwBZLKFRHFqEajG5B0DgDp/Tp5ElzNo93IGieO4RirK64KkHBBHY0Adg4R9cBkwoLdK7rTNfj0iRYY4Oo+9ivM/C6zatqazTk4Bya9jgtLa7iSIQZ2j72KAM++8R3Xngg5Q9qnGorew7WtVJ9xUOpWtpE4RfvLWvoojuLdlCBWHt1oA5670azuLdnhjVLkcisr+xZr+BkvThl+6a09S81NRZEfY+eAaUSzQ27ee4344oAg0jS5bCzcEBwOlZOqSq0bFkUMO9aVtq8saSo3Kmub1y8XymEbjJoAos0cgLAgMKzr8LIvynp1qpLMEQ4fk+9VxMWXaWoAlEY25NQ3UatEQwwKIWZpQhNS3qMRtPAoA5a/gCA7RkVkNjOAK6K9yuV25FY8lud5Kg4oArSRh1G3g1q6cjKgOOB3qrFFlsY4q5Pc/Z4PLFAEeqXRK9eBWHJKXJyOKW4mZ3IJyKiHPAoATFH86v2Fq9wG+XgVUuIzHKy46UAEIBfJ610unOv2c7u1c5a7SxBHNb9rtWHFAD1IebpxmteMqsQ249xWXbIS2RWlFEz8jgCgCwZP3RKjBrEup2MhzW45xCQo5rnrpCztjrQBSuic7uoqlK20ZAya01jLgr1NQy2ZA4HNAGOeSakjwRjvVqW0YLhQc063thnLcGgCu0RVTjk1GInLdK2kjhLDkVox2tsQGOMCgDFs7SRiPl4ro7S0UR8nmno0GzERFSKwUHBoAjeMo2A2RUN1A5GM5BqUsoJ5qJ5Vj5dhigDGvbKTfhRVf7Fjgtz9a3ZLqMxkKQSaxZQxkJ3UAe8fF7XTZj7HE+FIycV4/BNJPkOSQTWp4muptXvvMlYtxUFjbmAjcMigC7b2TrbFmUlfWo7S5mtblWTIAPWtuG6JhEezKUlxapJGViTr3oA93+F3ihr3T442O5lABP4V6UbuQqC3KV8meENan8P6iFLERk4PNfSPhfXoL3TwzMGVh60AWtVXfE7I37sjkV8yfFnS3j1OWaH7hNfUDW4mifDfuzXj/AMVvDc0llJPbgsB1FAHzvBePA2Cc+1attflhkr+FYt1btBckycYNWDcx+WGXGRQBv2OsXWn3sN7ZzPb3ELB45EOGUjuDXpl0th8ZdOku9MSG08e2ce64tRhE1ONRy6dhIB1H9Onh7SyXRwOB7V2vw9tLq01SC+tPMSaFg6SISGUjuDQB6X8N/DMkUBa+gaMg4YOMFSOoI7V2txPFZZjtkyg6kV6roGmRappcGoata2/266gxN5TAq2R97jjdj0ryfxjZnRri501ixmByjHjep6H/AD3oA5PXNZ08uQoHmj+dZ+n+JxDP1CgdPeue1+0kSVY9n71j2qvqmmvYW9u9ydrMM4oA7+BItan+0b/LcdPeuc8RSS2t2Q8uUHFQfbnttPjaNiuR1Fch4i1KSef/AFhP40Aal5rQjQ+U2Setc9e3bPl93XqKz2uAr8n5j2qrLdZbB6GgC1NIJEyp5py58teeapW7Ak4q3E3IzQBct5Fini3nmt7WbdRbRzKOCKwTGm6N5DwK7LV0WXw5FLGPlUYzQBw9yuTnbxWebfcxwODWykTTJwOM1HLbNF87cLQBk+WlujM3WsHUJ97HBrS1i6VmKxmsHaXJLcCgBnGMk81PawmVxjimQoHbbit7TbMEAmgC1a2zxW+QODWVfQZY8fjXTIr+XsHSqs9plTuHFAHNwxqnQc1qQoTHyMVCYgjnA6UJNI5KFcAUAWopjA2c8VpR6nE4CnAPrXOXEp+7VbzinJ7UAd0jLIuIzkVUubUFsIOTWLp1+VAO6ukt545Ic/xetAGK1u0MmRyatKq+Xlh81SXGASQc1QlnxkGgCO9ljjQ4HJ71h3FwRkKeTVq9kJyDWZuXB4yaAHQzMG6nmrpuXCgZNUY2BYAip5W2rkcmgBXvJEb5DVq21VwwDmsp23HNNoA6dbxZenWqN7Iwzk8VlwSsjDBq8+Z4+vNAFLznDZDUv2hz3olhZB0qGgD0zT7YiF5JRnjimLcRruWThu1V1v5EfA+76U54VvSXHDCgDXguwIQoA+tdfoFtBc6e5baJMcZrzaKYxv5cnBFdDpF9MBhWIFAFDxJC8F23OAD2rqfhn4ulsb+K3unzbsccnpWFrW2eItL9+uXilktZw6EjBoA+1bG6hmgR0bMTDPFVtUsoLyN4XwY3GOa8q+FHiz7TbLaXcnI4GTXpjzxsnytgetAHgXxH+G01vfPJZfPExyMDpXnsfgnU3nEaxOST6V9QakTKGAIcCudtp5Ibv5oRgdDigDzDSPhbqiBJbtQkfvXqGh6Va6DYjEYd8c8VpvPf3jDLDyR2Appcwk7oy57CgC/pviTV9I23GmuFgzl4JBlG/Dt9Rg1reJtb0bxZpUd5Mos9XswT5btxIncBu+OoB56gZzXNhbjYZLz9zD1ANcvq1xEt2EgBkQ8ZFAFS6R5daFyAGhU5FZmvwvrWqpvOIl7CtLUlltYkFs2TJ1UdRUcbpY25e55lYdKAOa8QzLYR+RuBUDArz+6ud8xbNbnim68+6Yg/Ka5eQruwfzoAkZw53MeaiL5NMJycdqRH+YigC3buc5Qc1o25DMNwxWXazFJOlacTbucUAaU6oIk5yPau905UvPB7xBchec1wEG0RHJz7V2XhC7Y6Vcw4yhU0AcpzEWTPyg1n6tet5OwfdFSXUxjvJlxlcnism+mEgZcYoAwb5tzEqarqjSAE8Grjwbqv2FgXAYjigCvp1kZHGFOTXTxWf2eIGQgGp9NgijQHHzDpVTVpJA24t9BQBPFPGnXrSPJ9oO3GBWC91lhzzVy3u9o6/NQBYu4YYl+X71ZrHaDlcfhUs1yJH561HcsfK9qAMe7lG8jHFU3c5x2qe55ztqnQBPAX3DacCuq0iXdGFauTiYlgM8VvaRKdwFAGrfDC/LWXKCy5NalwwKmsqRzyMUAULgE8noKz5CGPyitSVCVOelVBHwRtIoArIQBmgux47VOIwo+YYFMMkan5VzQBXoqZmjPOKTcn92gCOpVnZQMdRSKmfmB49KZ1JoAn+1EryOab5qnkioKKAO1l4f5elWbC4EE2JOhrPkYqeDT0wxBY0Aauo22f3y9DzSafeMuFY4HrXU6c+nXXh94n/wBco4rjJpE81kUYwaAOjaaGeDDHLVzd5ERKQOlW7C5VflIyam1ZVMIkQYoAr6HqM2m3sboxABr3rwnro1WzQFuQBmvnJ2+TPeuj8H+JZ9KukG47M8igD6Gu1wuIjWFezNbyAyJkHvVvRdVj1S3R4yM45FLqiLKpOM7aAK73rWkIuVYmP+7WZN4uCEypbhj2FLFOksUv2nKxoOhrm1uGnu5DawhgOi4oAfqniDUtVY+e5ji7KKhtHuo1Ito/Oc1NF4fupC99csI4152ZxSaRfvb3zPbqDtGMN3oAg2X0EvnTkrJ/cPasnWtUznzMGT+VWPEGpX15fMzJsPsOK47V5pBIQclqAKd9cJIzFuDWRIV5HenzsWY7utVWB60AIHAyMUikEfL1oTHJxSRY3nHegC1bgcbutaiHCDHWsq3PlP8APzmtq1CFCX/CgB0THYSvWun8IXTqsqEdQa5xHRAelXbLWrfT8ufvUAR3y7NRkby8jPSqFzEJnJ8rb+FXJvF9r9o3iND9aY/jC0mf5oUUewoASx0eOZcyfKK0Y7CO2j5wR2rHm8Vwu20AKvtTf+EhidTlunTJoA2PKRF8zIHoKzb+FbhCd4DDoKxrzXmkyFOBWa+qO5+8QaALF1CYycjmq6O4bJPNSRXyzHZL19aS5CoMg0AKtzlsFeaLi5bZ7VR88LyOTQbrIwRQBHJMMnb3qAnJqy8SMhcHn0qrQA6MEsMHFbWl8MADzWIM9q3NDhLOMZNAGxMp8r3rKkOGOa2rnMYx3xWFd53GgCNpCzDPQVHcXAJ2quMUxmIGO9QlcjmgCKd3Y4PSoKmk4XGcioaACiiigCeCNmBweDRLAyngcUsDkYA6U+WdxxxigCqQQcGkp7uXPIpAtAHVYUN8xphVt529KkaME8miPjNAG5oEiFWXJ3fWqV2gF04AxzTNIlEU+cc1PqsgLh0GG9KAIIyYpAccVrtKktvhhxWaGMltuK8inWdwGBQ0AVL5FTOzpUELhf8AerTv4h5e5B9axCDvyPWgD074ba60Fz5U7fIeK9Vh1WzmlIVgWr510q5NvKGU/WuktfEH2aUMD81AHr1/b2t4rZGzHbpWRbWp02U3Fsm5R1GK53QvFCXNyFumwtdUmow3GEt3G09aAL9xpy61ZG6jmCOg5jz1rlF037bOyW58iZD/ABd62likt5vNt5SFB+ZfWrzPZXaeacQTKOT60AcndmO1heDUUHnAcPivNdfnh81xFgt611nj3WFkcxfeA43+teaXM2XJBzQBWZixO7rTWOU460jNhvm71G5+bjpQANwvvTRlcU5hyOc0A5O2gCeIlmXdzWspIQAjiqVhGC+HNX3cgFSvHrQBRubhhkA8CsW6uN7EEn86v3cbNuZTx6VhyZ3nI5oARjknFNope1ACUuT60lFABRRRQAtSxsWQhjwKj2nGccVfs4YzGS55NAGeaAcVJOgWUgcLUZoAcmcg5q8tiZU3r1NUo1+YY5rpNNw8WAOaAM+30t+CRxXSaXZiADYMsadAjbSCOKv2w8qMnHzUARarGkcIOPnNczdRkcmulvCJIiZDhu1c5dsRkZyKAKTbccVWMG5uWxU8hx0qKQcZzzQA17IBMhqqtEyg5FTmQjgmk81ujj5fWgCrRUjlS/HSpEEYOe1AEXO3HSmmp5nRhhar0AKSTSUVOluWUH1oA6nblsk0wNhjxVtgjHioJkB6UAR2xdZgwq7dNuAZhzVGJikgBqW4dnxQBatXZlPHHpUOPKnyOCe1OsZSr89aW6wZt460AXG3PDyOT2rHuImiJPatK0lYnB6UahFvTORigDLgmK/SnyXX92oTgfKBxUZG047GgC5bXkkLhtxxWzaa1cLKhjkIA965oggYJqaBii470Aez6H4iimtljLZmxzk1Z1Fn8oyMCsfqK8f0zUpLS4Uhj19a9RsvEMWoaWtvIoJIwTQBwXim4jeYleVrkZ25BX7tdT4wiS2mIToea5UkEc9KAGSDGGPIoYqF+tIEw2ScrSOhJyORQA3/AFfXnNTRLnAHU1Epzwwq/YQ75FGKANDT7TKfOcH1q+bYzRmNRlx0qWWFoLVcjnHam2N1tdf7+aAMS7gMKujghxXL3APmnIr2PVNItr/TBKfluMZ6da881PSXiJVlwfXFAHNAZpK0GszGeTTDbKCCKAK4hY4wKf8AZ2AyRWjb24YZ6Gp1i3DaRQBlm3Jj+XrTY4sDBHNa6252kLUJtm5yPxoAz/KJYADirXliKPJq1FbcZx0qtfSYG0DkUAZ07bn9qiqSTJNPii3kUALbDL10+jIcbdvXvWNa2wVge1a8WorbfLGAaAN2KJ1baaS6nFshMhFYd1rjom5ayp9VkulPmnigC7eai07nBwtUmlLEnOaz2nycDpUsMgPSgCZ33DHeoipxyakYg0wnLUARlcgjvULh1BB5FXFAB5pmwhiT0NAFIDPSlXkhfWrXkAZIpsUOW6HNAELxlTTVGeMVtw2JkGWqxFpa5+YcUAZFta7myOa1UtV2ir0VqkZ+UcUjmEMRmgBV2g5Jp4YNx2qqwLDPapUdSAOlADlj/eZPSpJRsTJFODKAM1oSxJJY7h1oAyrU4y3c1KnzsSRk1VyEJA61asiQ+OpNACwITMFzgVuzaOZLDzElBAHIrEuUZJRtPWrttcTwxbd5KntQBi3YCNsxyKh4OM1qX8CyLuxhjWTtKZBoAWVQDxzTGJHSgP260FsUAJuOcmtfStWe3YBc1isCfpSq2xht6UAbmtzteASPWEyBh1q/LIzQjPSqG0l+DxQAxo9v3jxSqMHIPFSyAEAPURwflU80AIq72PFdR4b04zHL8AVzlnGzTBe9dlaXC2dmQxwxFAFm5KxgxN8w7VmNGsTeYF5HIp9nN9quOuea35Le2NuN4AYUAYkutSGNVIOV6VBJd/b02yJhx0NS3scC8gDiqUMjSTAQR8UAY+o2Mm8kVRWAk4bjFdxdQHydzoM45rjNYnAkKp8tADZJUiXAPNV2vwoIBrNdiSfmJqOgDWhv93XitS0v4pBsZfxrmI1LHircLbWwKAOom8tYCYyK5i8l2yE9c1pWspKMD0xWNdAm4YdqAIt535p8Uux9x6elRHg0lAF37Y+DxhaWCYkNxzVLJxjtToywOVoAfMWBIY9aizxildix5ptABUqtwAvB9aipV5NAFxSceppR1yetOtIyBxzRKCrEsMUAAyxqVV45NMjAIyTilQHJOeKALdpamQ9OK0EsUHOOlR6XJnjHFWrqXy1O00ALhVX0Apsl4oTFZrX24lTxVV5NzE54oA0Zr3CZHFZ7S7iTu61EWL8dBTOBQBvMrAZPB9KYF8z5hxinSSs0mT0qM5DEigCVjtGeuKswXZaMoelVUfK9OafGp6ngUAMcDzSDVqwUiWqpIMvPSrVod0vynFAF29UAA55osIizhm6U0xFpMM2aUu0EmwjAoA2ru2tpLcMvDY6VyeowFJOOldBC4ZACf1qrqFuChIoA5kttOMUA9fepZozvPaovu0ALGAwINRAYcqOlLkhsjvTiAeV696ALMIZlKnoKjRNzkIelLCxxhfxqWGP5sr1oAjmGxDuqmuMlqt3TEtjNVVX56ANPTmRP3j9qhvrxpJcljtqTy9ltleSR2rNELySYweaAOj8PsrMGzjFdeXt3t8FucVxNmptUUHoa145lZVTdwe+aAI9TZYyQMketMsLgxEeQoJ96u3whECpjdnvUVrCkMJfIUdeaANGSO4uLYsQAMVwmr2LmZjjiurtrjUL1mjgyYx3AqaTRbiSJmA3kdQKAPN1syX+UE4qUWbFs7f0rpZLdYXKtGQw9aRYiRkrxQBiLZnZuxinJYu2CF/StwRjGHGKmWWOLC4FAEOnWKxMrTL8p68UzxJoMLlZrI8HrXR2aJPGA2Oa0Z9Oh8kbaAPJJ9NljIwpxVWSBlbGK9VubS0Ee1tu6sa40mzLZDLzQB5+yMpwRShWwSK7K40aEfdZWHtSHw08kBeLGB2oA4ykrRvdOmhkIZSMetVfLxxtOfWgCCrFtAXOTwKai85dSMVaRmJyvAoA0bKHedqYzVe7jKTFXqWxn8mXNP1RASJVYHNAGc45+Wlj9zTg3GQOaYeWyRigDRt5PLXINV7id2bg8UgbCVBnDUAG4E5PWjHzZHShtoOetCnHPagAZs8jtUZYE9KeAC3B5pDkHGKAOgK8803p8pFP5BpFcHII5oAWMg/KBzUhzsIJ5qBW25PepUy0eSaAK5IHDdatWpGPlNVWCsSB1qaAFeKAN/wAP2xu75EfoTXTeI/CF0Qr26koR1FZfgEB9UjVhnmvWNfuGh0po4CC231oA8ht9Ke2cLM31q7PZwyJhWrKuJLgXbmRyTnpmr0UhMBZjxQBzmr2nluQlYUylGwa7C6i86NmXmuau4yrnIoApBhjkUgPB20sgB4HBoU7RwKAH24w2TxWgjBULAVnq6sMdDWjYlTGVccUAUpk3EuTiqoJa4VYzkk4qXUn/AHhVDgVoeC9KfUNWiUAn5hQB1VroBj0dJ5FyzjgVSh0ZoZPMdOD2r2qPRore3gWYBgoHHaub8QQwwzeYijaOMUAeY6hAUfOPlqqssZO0Ng112oWCTI0ifePG2sG78KXNrb/bpDtVugz1oAgFwduzbuA6VNb2l1qLrHtKRZ5NO0SymuJM+XlR6iuzjuEtoBE0aqO5A5oAu6HZ2en6eYUlBmI5NZ26W2ncwtuBPIrOvZIVn3wzt6kZqOXV4cjYx3DrQA3U/JYPJLCA9YMco8wnb8uelXNU1PzxgAVieaVk3Dn2oAv3rI8W7btNZgG/ljU8kjTDDDAqJ3CrtxQBbsrh4SMN0q5Jq8jgoo5rF5UZzV+xQS4wPnoAX95LuLE7vSmLZzsCXBC+tdPp2hsALibgdcVq/Z4pMbwFj7igDi7bTZJEJhYvjtTllvLU9DtHUV1iW8NjdiW13NETyDVvWbSG4hFxbou09RQBybm01NFV0CSd6yNd0H7CgdAGB5yKv31q9rKJ4gQOuKnN217ZlZOSB3oA4O4jJH3cGmpC2zpWrPE32hgVFSRWueGFAHPSMy9BzmphLviwT0rSvNNxzg1mvAYs7gaAEXgAilPzYOOadEN/1pZEK8d6AGyHKVECMe9Ss3y4xzUOwmgABx1pxYdKjZjnAFKrLtwetABgg7hS7pDziiMnOKupDlQaANLzMDpTWPy7hTxjp3qORscCgA3b1x3qYYSLnpUEZzjHWrDsGjwRQBAqjllOadHncSDTfucr0NOjxyehoA7PwBIRqC4GWNemHTZHMs00nyFehrzn4dhVumc9VGRUviTxfPFdSW4fCdKAMnXoVj1WRonBGe1Ngkdh833ayvtQmnLlsk1pW75XOfwoAs7gqHaOKxdQh83JUVt/KyZ4A9KryKsnygYoA5SaDHWq3IytbV5BhyprNnh2N1oAhTb0brU6TGLIHIqu6DPJ5pA4HGaAGzku+fWu/wDhmqpfIxH41wQUu4ANek+ArSSLa7D5aAPU7zUVW3KOfmx1rgtWv8s+DnFb2tt5UAYjqK4C7u0EzZPJoA6Tw0sGpXGZDh15A9as67o97qdxnIWFP4enFc74buRDfBgcsa7W8vJvsxOfmYYAoA5e5vl0xBFCqhl4PFYtxqE9zJuY4Wl1aKbzmeYnk1Xt4/MjOGG7sKAIL5Rt3ITn61m/Mxxg59a3fscyoWlQ7aqmJjkKh+tAGSFYHbnmmlSrY71p/ZmU4wcmke22cMOT3oAoAttwcVETycjNXmtc/wAXFNW3JfaOR60AQRx5GX6Vs6Pp0jsJDwvao4rBgyl/uV0gcWtko7HoKAL0F2FtjFJ8zYwoFb3hrwpd6gpmvMxw9QD3FWPAXhdZANU1UYhHKK3eu2v7tn2+QNkC8ADvQBlL4Z06OHy3X5umTXP694TuLaAz6c3mR90FdW7sSC4ODVmDfburiQNG3VaAPD78PhkZPn7qRXNSb4LogDAPava/iF4fjjVdTsl68uBXjeusWmEiDBHWgCuLVpLrPY1cW0VJfmFU4b3y2UnrVm4nLAMvQ9aAJvIhkLB+1YmrWsXltgcitKKcYIYZrM1QnDEdKAOciDROSTxVll8xd2arsd8hzwKnRQV68UAQuuBxUDK3arDkA4zULtzgGgBOMbR19ajWMgmnD0HWnjOAooAdEParSvhR1qNEYLyKdnHagDTHzMSeKTAOc0xju5Bp4Vh16UAOVVQZB5psjbR707A/Go5M7sdaAGFiR6U5ATz3FNfr70+PLOoFAHdeFZYrLSZ55W2vg4rgdYujdXsknqTzWjqmotHZLChIGOcVzyvuP1oA0tPfjOK6C0A27gfwrGsCFQZAxWoL63hTB60AaPRdx4HpUPmDfkdKzH1hGbB+7S/2jFIRjigC3OI3bLH5qy7qJSTzzVsSRSHLGnSJE65BoAxJ4gqYzlqrLGMYPWtiWBWBxWfcREDAH40AaGg6b9svI41PUgV7honhK5sEt5dwaLgkZrxjwfcJa6hGZT0YV71a6pJdRRC0k3KAOM0AS+M7CFNNWVOSByK8QurbzdQIyRk16fqetsmom3vM+X0IrjLz7J/bJbP7smgDHtC+k3yu/wAyds11llrAlYvKuVxxWVq2jO3+lRHdDit3whZ213ZTJMMEDg0AYGtN9qDuDwKg8IWQ1G6ZGbBXmp9ZtDbCcKTtzVPwtfLayuQcP2oA6+6cLbtaNECVHB71hNb+Wp3KAKvWeofaJmLj5/Q10+ieF5tbDSSjy4h+tAHEQQh+AmfeludPZwFCcHvXo0nhNYyY7Yfd6kjrWRqGjXKgrEnTvigDh5NEIGA3Joj0hgNoNdCunXYcrtYt9KmtdA1CeXbtK56ZoAwv3cMYhILSdq6/wl4Ta8eO81IFbZTkKe9bmg+F7DTsTaqA8vUCt+ecFAsY2xDgAUATX1xFJBHBAu23j44qj52ZlVlxEOBU0jA24ULj0qorSE4dRt+lAFq43B8gAx44pkCBy+5zjsKbLMSm2Pp3zToCgiJbr7UAWJYxd6PdQSHjBxn6V84a2hi1GeFWzhjX0VrtzFp/hu4mY7cqcH8K+aLuUz6lLKGzlj1oArtEU5arYnHkBR1pZ42IUkVVnIjIUggmgC7b8rkis/Wn+X5a1LBBtBJrK8RnDEAYoAwD82adGT0zUSPyd1OVvmoAdIMDrzUGPU81YkGPmNVyOcmgByoD3qWLG4CmKuKkiABoAtshVQSeKi3imO5zjdlaTK+tAGjsI6HIp6OQMGl2hTwaQrtBbrQA5GABz3qMZRieooJ+XkUxjhcjkUAGRuJNWLEAOXb7oqp94fWpJn+zwYPegCDVLhZZTjoKobWc4j4J6UrsDzU8GQyuvUc0AaUWha7HZC5kgkFsej44qtsOCJetddF4l1m/0qPTSrC2UYHFRweHZp13SgigDkvKTP8A9epBEo/irq38MgfNnpVSfQZCCy8AUAYtuASQTirsILHYDnNQXOnywHJBApttM0UqigDY+yskQCqTmoriAJDgrWzZXKmNPlBHem6mqvjYBigDjpgbedWU969H+H/iVLe4jSY9cAZrhNRtCeaNFkC3KjoQc5oA9e8TLHe3Zk24LDhq8y1X7RbX5BDFQa7mDVFls0WXGV6Gq8klqB508ayrQBgW3iV1s/s7qQnvXQ+H7rdYySQAkAc4qy0GgalpzssSwygdq5ywu20aeSNRvt34/CgDWlmS+hkUDkVyJjay1EMThc11MDxgNNCBtftWJrVu0mWwfUUAaGmyrJrtq2dsZcZr6QaOKPT7b7KAgIGSO/FfKVjdkBUbh0OQa+ifh14lsdb0BNNuZljv41wuerUAbd0UV1WIbWI5PrVG4EYkwVAz1OKvz20kcRjuF2sv3XHeqB2zoc/fWgCsYIY3L7QfwqQnehKYVh04qNSN/I49KiuYm+9GxA9KAGGN5CTd5YjpXnWs+JNRuNb1pItah0HSdHaOJ5jaid5ZH6ZB6DPp7evHpdpIcESfN7muU1nwfBd6xcX9lf32n3V0giufszLtmXGPmVgRnHGaAOY1vxdrFtp+iSjUJG0yeJ2n1exsRJuYMQo2NwowBng98dK7DwTq/wDaWjRytqseqh3YLcCHyiR6MvYiq0XgkWNpYwaZrOqWC2sXkgRyIwddxbLArjOWPPFa2gaDpnh2wS1tGkb5jIzyNud2J5Yn1oA0mgYjZHwDzmrVrBvAhX5sdSKb87qMfKvc1y3jXxbDoVi0Onyh7lxyR2oAwfi94oQouk27Z2cOR615TFEXdSv1NPuDcX921zMSzscnNadhYsHWRhhe9AEd0WZUKrgLVC7njnddy4K1ua7LGIFSHAPfFcpJG7SgEYzQBvWGyYcnAArP1eNJtwJHHerDsILZUUYJHWsPVpzGNitkmgDLdAjsM5FIrAjgU4LvHOSTU0MI+7jmgCLYx5PIpwRSMsKtvC0Y9qrPxy/SgBBHnoeKYFCt14pssoUfKeKi84MML1oAndQAShqmwbJ5qV5Qideag8/1FAHVlBjng1E+cYFSXO4jjiqyM3mDFADn+6AajJGMCpp+3FQBS8qooPJoAtWFu0zlsfIO9U9WYNJszwK37tv7P04KBgsK5KWUvISe9ADFG5uK6DQdJkuZVbaSKxrOPdOoPIzXqPhmOG2tkcYLY6UAaGn6YYrZd0argVYl3RJgfdq60geLexGPQVTaRHU84HoaAKwcMpx0pmfMGAOBQWVSSPu06Ehm/wBmgCpe2S3Me3aMDvXF6xYtFMfLGFFeiyKVHH3KwNct1ljO0YoA5ayvpIiEHatZrjeAawZUMcuF6ir0TExf7VAFiYpICpPNZOwwXQHQE9atNxy3Wmz4dQSeaAOjtHBtlRjwe9alssccWJCGU+tctp0/Ko54FatzdKsZ8s8gUARarqUcMnl2g59AKpTalkKt1GUJ/vDFW/hlZLrvxAs4bkjyxKCyt3A5xX0r8VPhTo3imxhi0qKOy1FAMMFwG+tAHzRBevEVCnMbelbMc1s+1ZCCGH5VheLfC+v+Bbw2+qQO0OcCQD5SPY1Q065W4XzEk5/u55oA0df04QTiW1O5DzxTNN1OSznSZJGjmQ5BXipReBYtkg3Z9ajaxSeLzARuPQCgD2Pwn8TYbuBLbWyAQNok9a7QPY3kQn02eNs9t1fLMqSRHbJuUDpWlpeu3unsptbllx/tGgD6Gu0uUG+ONSe4FROkjRA4O49RXlmn/EzUYGUTMHx6ittPiOhcSMgyetAHapmOI7QS1OtI/OHBxJ71xj/EGyJLKvJ61mX/AMRIkB+yjaT3oA9INpIHJmlXA96ztQ1jSdMVmuJQ0g6AHNeQ6j471G5ykcrBT6GsKe7u75syM7E+9AHf+JPiFJLG8NlhUPGR1rzqRri+uS7Mzlj35q7BpEsmHlO1PU1bjktNNbdGRI/YUAJBaCyRZJcZP8Jp11fgx/Lx9KqPJPf3BkkyE7VXuAittLZoArO8txKWPQVC7FGJI4FWotxbaPu026MajBoAzp78hCxH0rGy88pkbpVq8PmyYi+7nmiNQoAFABEi43VNEyhuKYSAeBxTQ4DcUAS3UoPQ8Csu5kLkKOgqW4Yl9uajKCgCvJzhTRtwAEHNWViyOalSIEcdaAKJjDnng0CIDjFXhErZBHNRNEQxANAG3cSk8AcVFbruk4NRFuxPWp7eIn7p60ATuA74HWtjw5phnuDJJH8qc5pNE0Z7i4XJOPU12s7Q6TpzRIFLEdaAPO/Fl15lw0YGAvArkmkDPgdRWz4guC9yxx1NYgILcDmgDV048j1zXbeH5HUqM5zXD2LBXAPWu58NyLvUMKAOuiiMah2+ZT2qG5hSXmP5RVp7tYVVVAaqn2kOxGAM0AUJYXU4HSpIfvKA2AOop87eUhLEc1jATtMShOD6UAdDMzMBt+6OtZGrgMCV+UAVZhMwj+cmqGpSHYxbpigDjdScCYkcYqSzk3jJNF0q3ExzwKnsraM5AbgUANcNITmoZUYLnNWSSjFR0qJyQCTzQBPp67jluMVLeS+UwpNPIIyaq6vIcfKKAI7W8utJ1aHUbBiksbBgR7V9O/Dv4w6V4kgt7HVStnqwAVZT0Y4r5a0+8XcEn6GrV7YquLm0fZIOQVoA+1te0q01yya111Uu4nHyOcV84fEH4PahpNzJe+HS09qMtsXqBWn8DviFKL4ab4lvGeI8RtK3Svdri7aJyY8PbOMgg5GKAPi8ao1q5tr+ArKpwcitGG5SRA9vJkj+GvovxH4B8P8AiZZJJ4Vt7tv4k7mvIfEXwe1TTfMn0qQzIvOAeaAOWkvjIALi3yB3phWxlXCP5b+lAvL/AE6J7e8sMsvBJQ5rKe7idyzxMh9NtAGgtipb/Xg02eydMbZc1UFxA+B5jLV1IovLGLjOfegBP7PbAYSZzVpLK2RQZWz61m3UrW3CS7s+9VXv2xg5JoA6GSOyjQeUQaRb2KJdkajPrXNLduThUY/hU1vaX9/IFtonz9KANma6uJv3fmlUNVz9ktJAZZQ571f07wDr94A2x1X1PFbVr8MLmYFbhz5vbvQByWpa1vQRWqYHqKyWuZY+ZATmuy1LRrbwq7JqG137AGuLv79Li4JjT5CeKALljctuPPWodSlG7g8mq6PtTKnk1Ww7PlzQBNF90kdaBzknikDdh2oZiw5FADy2Eziq/XJzinAkHB6UjpnocUAVJCxf1qSLOfmqvvKzbO1WkB3j0oAnQDoaeox2pxVSB60A7etAAiqM7upqNoMscGpSwNMO7PegCeCPznx2FdHo+lB23SMBGOpNQrZR243PgCqV/qbKpigbCng4oA7iPUNMto/Jhf5+mc1k6pJJ5TOJAynpzXB+c3mcMc/Wr9vqLsvlu2RQBnatu3sx61lpuznvWpfnc55rKkVlOR0oA0bU5IPeuw0W4KhWHUVxFtOEUE1vWF+I1GKAPRbSUSruNRXExjclsbawrDVVWPDHrUk1z5xzvytAE1xeu5IJ+XtUmnSsH+fp2rMeWLOCwqcX1vEBuYcUAbU9yduCQD2rntRunkVkB+bsKi1DWImGY2GRWXBMXm8+R8AdqAM26kuFlKlSK0dMcsmHyDUd/ercT7lUcVH5shIKoRQBqB40yG5NUpZhu2pyabb2txcSZYEZrQi0/wCzSAtyaALGkwFlIYcmoNWs3jyK2dPaJWyWAajVfKl+64zigDgZwFfHQ1o6XfeXiG45Q1HqcCLIWU1n7jnJHAoA3NS08x7bi0kweowa9T+FPxWeJY9F8RNuhOFSU9V+teR6ZfgHypuUNO1C0KN5sWSOoI7UAfXMzFArK4e3kGUdPeqr3VxCxRW3KemeleH/AAz+I0+lyJp2tu0tkeFLfwV7WksV9brNpsqywuMgqelAFW4nsnYpeafFK57iPNYuoeH/AAxOfMubJoyeyritiWO6hyVXc/aqzrLLzdREt6UAcrq/w40DULbzNNdonPZq5K6+E9/GnmQTqy9hur06aJUy5Xyh6E0kCSudyXIVB2JoA81034W3hPmXUyDnoWrctPh7p9vIDcyhj6CuqMTyz4N6oA7VFPaxrJua5B980AZM3hXw/ZsrlCxPatiyt9NtYh9gt0Vz6rUTzaagzPKrEe9Q6vqmn2GlPdRzp5g+6tAGo81wtsxuZI7eIdzxXF+JfiPa6XayWtgfMn6eYDnmvO/EnjLUtckaAOwjzgYrCTTWhXzrkls88mgBdU1C91m5ae9dmU88mqTOqJtRc1Jc3GRhOF9KWyhM7cDigB9qmYy0mfamvlck9K1DGqqExketVpbcPwOlAFNGB6YqQlcdqZNZSL9w1UnguAM80AWiFzlulU7ufJxHmow0u3Dgirlr5BiO/wC9QBQUA9PvVbjJKgDrVa5CxMWTvUaTlQPU0Aa6jcoB+8KefQ1SimO0HOTVlZMr81AD2G3kVGZeaYZsAiqbSjceaAOj1O+eU7egrHPzMTmrV3LuHTmqWQMUAIcZyOtOjlUtwMGkc44XvTOEOD1oAtzpuizWYy4znpWrG2+PbVG4hJYgUAVAwBxjirMTEgbTVVztfZjinK+zGDQBofaXRQM9Kb/ajgYDmooNrvgng065skBypxQBGdQlY/eNO+0u45Y4qt9mO72qaODIwelADQ7b8luKsgzT4RCQKSK3GcGtS0hHYUAW9H0oMAZW5rd8u3hTa6rkd6xYxJG/DH86ZfXD7QM/NQBo3WpLApVFAI6Vh3WrzyNgZqlcPIT85qJmIAAA+tAFoahNuzuINWEvGcjc/wBay3JwMdaUHjnrQBuNClxH8rZNZk0UkRKlcio7ed4HBBNaYvFmX5gM0AZkJG8ArWzbXKxKI3+ZD61nTzKhOFqASknnrQBuX+nrJEJE+6ehFT6R4i1rRE22k8hi9M8VX0jUwg8qcZQ1pTxIyEwYIb1oA3LH4n6isLJPy/YmqUvxE1Lzw5Ymucm0987iv5CnJpwdDx81AGnrXjXU9R2HcVx6VSm8VakbdUWRhgdjWa1nN53l4xSvZyxsFbGKALX/AAkWoFQomfP1pBrupsuwSOR60QwwAjPWrpeEDEajHrQBmPqF+xO92qGRdQveJJG8v0rXEPm5YJ8nrimTSCFDtOAKAIrEQWUR+0KNw71naheyXDFU/wBX2pt3M8uWk+7VFpSR8nAoAfBB8/zdDWhgQKPLPXrWYJSgy3Wopp5GPymgDXN8ifL1J60ovYwvHWsTOep5o3gHg80AbKX6bs9qlE0dwcg4xWFkY4podlb5CQKANedEJORVGWNDnbUsUm5MP1ppIUkUAZ0obBGOBVatK4GVPFUVTrmgBEkKn2qT7Q/XtSRxgnnpTnXHTpQAwzsT6UhG45z1pv3m4peRxg0AbErZbmocZOaKKAELfNSv83XrRRQBPbyYOKkljycg0UUAZVyg3E96gj4bB5oooAnj/dHK08uznOaKKAFBY96nX7uaKKAHQsWYCtmFdkO49aKKAEhucOQRnNLdJld2eaKKAMmUEk7jUIJzjPFFFACY5zQDk0UUAJvweRUqyFcFaKKALCTLLGQy8+tQONvSiigB0chTnvW1p18ThSCaKKANZZXPUjb6VE8jI3ycUUUAU7l5Hc8jPrSLHNIuGcGiigCWCxCgljmibYPlQYNFFAErah9mt9ir25NYVxOZZN3IHpRRQBXkmL5B6VTILMccYoooAZuLHBNNUc80UUAK2APem7R170UUAKDgYNPjAY4IoooAtIuCB2olXvRRQA1wGjyaqPGCCR1oooAYgKrzzTWXepxwaKKAI14OB1qQSYGCM0UUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2 weighted magnetic resonance image of a woman with appendicitis at 9 weeks of gestation. The appendix was fluid-filled and measured 7 mm (arrow). The gestational sac (gs) is seen lower in the pelvis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27488=[""].join("\n");
var outline_f26_54_27488=null;
var title_f26_54_27489="Patient information: Thrush (The Basics)";
var content_f26_54_27489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15787\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/31/43519\">",
"         Thrush",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/52/34626\">",
"         Patient information: Mouth and dental injuries in children (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Thrush (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/thrush-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13396075\">",
"      <span class=\"h1\">",
"       What is thrush?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Thrush is an infection that affects the mouth and throat. This type of infection is caused by a fungus called &ldquo;candida.&rdquo; Candida is a type of fungus called &ldquo;yeast,&rdquo; so some people call thrush a yeast infection of the mouth and throat. The same kind of yeast can cause diaper rash in babies or vaginal infections in women. &nbsp;",
"     </p>",
"     <p>",
"      Anyone can get thrush. But it is more common in:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Infants",
"       </li>",
"       <li>",
"        Older adults",
"       </li>",
"       <li>",
"        People taking antibiotics",
"       </li>",
"       <li>",
"        People being treated for cancer",
"       </li>",
"       <li>",
"        People with HIV",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396082\">",
"      <span class=\"h1\">",
"       What are the symptoms of thrush?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with thrush have no symptoms. When symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        White patches lining the cheeks, on the tongue, or on back of the throat (",
"        <a class=\"graphic graphic_picture graphicRef56812 \" href=\"UTD.htm?42/31/43519\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Redness inside the mouth without white patches. (This happens in people who wear dentures.)",
"       </li>",
"       <li>",
"        Cotton-mouth, which is when you feel like your mouth is filled with cotton",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396089\">",
"      <span class=\"h1\">",
"       Should I see my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of thrush, call your doctor or nurse for an appointment. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396096\">",
"      <span class=\"h1\">",
"       Is there a test for thrush?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, but most people do not need it. Your doctor or nurse should be able to diagnose thrush just by looking inside your mouth. He or she might also run a Q-tip (called a &ldquo;swab&rdquo;) along your tongue or cheek and collect some fluid. That way, he or she can send the fluid to the lab and have it checked for yeast.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396103\">",
"      <span class=\"h1\">",
"       How is thrush treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with thrush usually get a prescription mouth rinse or a lozenge that has medicine to kill the yeast. (A lozenge is like a candy that you suck on.) If these options do not work, people sometimes take a pill that has medicine to kill yeast. People who have severe infections or other health problems sometimes get the pill right away.",
"     </p>",
"     <p>",
"      People who wear dentures must also clean their dentures really well every night.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396110\">",
"      <span class=\"h1\">",
"       Can I prevent thrush?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have HIV, your doctor or nurse might give you medicine that kills yeast to prevent thrush in the first place. If you do not have HIV, there is not much you can do to prevent thrush besides keeping your mouth clean. If you wear dentures, it is really important to clean them every night and to give your mouth some time without the dentures.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396207\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/52/34626?source=see_link\">",
"       Patient information: Mouth and dental injuries in children (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/54/27489?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15787 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27489=[""].join("\n");
var outline_f26_54_27489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396075\">",
"      What is thrush?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396082\">",
"      What are the symptoms of thrush?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396089\">",
"      Should I see my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396096\">",
"      Is there a test for thrush?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396103\">",
"      How is thrush treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396110\">",
"      Can I prevent thrush?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396207\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/31/43519\">",
"      Thrush",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/52/34626?source=related_link\">",
"      Patient information: Mouth and dental injuries in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_54_27490="Aortoiliac aneurysm on arteriography";
var content_f26_54_27490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortoiliac aneurysm on arteriography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arteriography demonstrating an abdominal aortic aneurysm and bilateral iliac artery aneurysms. An endograft has been partially deployed (main body only).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27490=[""].join("\n");
var outline_f26_54_27490=null;
var title_f26_54_27491="PTC Klatskin tumor";
var content_f26_54_27491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Percutaneous transhepatic cholangiography in a patient with a Klatskin tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following insertion of a percutaneous needle into the biliary system (black arrow), contrast has been injected and shows dilated intrahepatic bile ducts. No contrast passes into the extrahepatic bile ducts due to a Klatskin tumor at the confluence of the left and right hepatic ducts. A stent has been inserted (white arrow) in an attempt to alleviate the obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan B Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27491=[""].join("\n");
var outline_f26_54_27491=null;
var title_f26_54_27492="Sticky colloid FNA";
var content_f26_54_27492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papillary carcinoma with sticky colloid: Appearance on fine needle aspirate of the thyroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of a papillary carcinoma showing scant colloid which appears to \"stick\" to laminated psammoma bodies instead of smearing across the slide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Colloid from a macrofollicular nodule: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papanicolaou stain showing colloid which is usually abundant in the background of macrofollicular lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27492=[""].join("\n");
var outline_f26_54_27492=null;
var title_f26_54_27493="Captopril and hydrochlorothiazide: Patient drug information";
var content_f26_54_27493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Captopril and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23255?source=see_link\">",
"     see \"Captopril and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to captopril, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries, other kidney disease, or hyperaldosteronism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11690 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27493=[""].join("\n");
var outline_f26_54_27493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021847\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021849\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021848\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021853\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021854\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021856\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021851\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021852\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021857\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021858\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23255?source=related_link\">",
"      Captopril and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_54_27494="Epidemiology and etiology of osteomalacia";
var content_f26_54_27494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and etiology of osteomalacia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27494/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27494/contributors\">",
"     CJ Menkes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27494/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27494/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27494/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/54/27494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia is a disorder of decreased mineralization of newly formed osteoid at sites of bone turnover, whereas rickets is a disorder of defective mineralization of cartilage in the epiphyseal growth plates of children. Osteomalacia and rickets can occur together in children (open growth plates), but only osteomalacia occurs in adults (fused growth plates). Several different disorders cause osteomalacia via mechanisms that result in hypocalcemia, hypophosphatemia, or direct inhibition of the mineralization process.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, pathogenesis, and different causes of osteomalacia. The clinical manifestations, diagnosis, and treatment of osteomalacia and the etiology and treatment of rickets are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169360\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing prevalence of vitamin D deficiency in many countries, which when severe (25-hydroxyvitamin D &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [25",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    and prolonged results in hypocalcemia, secondary hyperparathyroidism, secondary hypophosphatemia, and osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/1\">",
"     1",
"    </a>",
"    ]. Nutritional vitamin D deficiency is therefore an increasingly common cause of osteomalacia in adults. Populations at risk include the homebound elderly who have little sun exposure and insufficient dietary calcium and vitamin D, patients with malabsorption related to gastrointestinal bypass surgery or celiac disease, and immigrants to cold climates from warm climates, especially women who wear traditional veils or dresses that prevent sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Hereditary forms of vitamin D deficiency and resistance, which are identified in childhood, are associated with osteomalacia in adults, but these disorders are less common.",
"   </p>",
"   <p>",
"    Osteomalacia can also occur in patients with primary hypophosphatemia due to one of the hereditary hypophosphatemic rickets syndromes (eg, X-linked hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets) or with tumor induced osteomalacia, an acquired paraneoplastic syndrome of renal phosphate wasting. The hereditary hypophosphatemic rickets syndromes present in childhood but persist in adulthood. These disorders are also uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone remodeling occurs continually on trabecular and Haversian bone surfaces. At any given time, about 7 percent of the bone surface is in the process of forming new bone. The osteoclast begins the cycle by excavating a cavity on the surface followed by refilling of the cavity by activated osteoblasts. New bone formation takes place in two steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoblasts lay down organic matrix, or osteoid (",
"      <a class=\"graphic graphic_picture graphicRef71593 \" href=\"UTD.htm?41/2/42018\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The matrix then undergoes a process of maturation, which requires the synthesis of a number of enzymes over a period of about 10 to 15 days. At this point, bone mineral is deposited as amorphous calcium phosphate that undergoes conversion to hydroxyapatite. The calcium is taken up by mitochondria from the extracellular space and transported to matrix vesicles. The phosphate is made available by alkaline phosphatase present in the matrix vesicles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rates of bone formation and calcification can be measured by histomorphometric techniques using double",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    labeling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/4\">",
"     4",
"    </a>",
"    ]. Tetracyclines are deposited as a band at the mineralization front and, since they are fluorescent, are easily visualized under a fluorescence microscope. After two courses of the antibiotic, separated by a period of days, the growth rate of the skeleton can be estimated in iliac crest biopsies by measurement of the distance between the bands of deposited tetracycline. In normal adults, this distance is approximately 0.6",
"    <span class=\"nowrap\">",
"     &micro;m/day.",
"    </span>",
"   </p>",
"   <p>",
"    Two changes occur in osteomalacia (",
"    <a class=\"graphic graphic_picture graphicRef61773 \" href=\"UTD.htm?0/32/520\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The distance between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      bands is reduced.",
"     </li>",
"     <li>",
"      The unmineralized matrix appears as a widened osteoid seam (more than 15 microns) and the osteoid volume is more than 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both features are necessary for the diagnosis because other disorders may show one of these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Defective mineralization in osteomalacia is due to a lack of one or more of these necessary factors (",
"    <a class=\"graphic graphic_table graphicRef70293 \" href=\"UTD.htm?22/3/22589\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newly formed osteoid that is normal qualitatively and quantitatively. Fibrogenesis imperfecta ossium and axial osteomalacia are examples of defective bone matrix formation and failure of mineralization despite normal plasma levels of calcium, phosphate, and alkaline phosphatase.",
"     </li>",
"     <li>",
"      Normal concentrations of calcium and phosphate in extracellular fluid to allow uptake of calcium and phosphate. Hypophosphatemia, due to vitamin D deficiency and secondary hyperparathyroidism, or primary renal tubular defects with phosphate wasting, is the most common cause of osteomalacia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"       \"Causes of hypophosphatemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Normal pH at the site of calcification. Chronic acidosis, as occurs in renal tubular acidosis, causes bone disease.",
"     </li>",
"     <li>",
"      Adequate bioactivity of alkaline phosphatase. Hypophosphatasia is a rare disease characterized by low alkaline phosphatase, which results in accumulation of pyrophosphate, a natural inhibitor of mineralization.",
"     </li>",
"     <li>",
"      Absence of significant quantities of inhibitors of calcification, such as older bisphosphonates (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"       etidronate",
"      </a>",
"      ), aluminum, and occasionally high doses of fluorides. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link&amp;anchor=H6#H6\">",
"       \"Pharmacology of bisphosphonates\", section on 'Mineralization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ETIOLOGIC DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different disorders cause osteomalacia via mechanisms that result in hypocalcemia, hypophosphatemia, or direct inhibition of the mineralization process (",
"    <a class=\"graphic graphic_table graphicRef70293 \" href=\"UTD.htm?22/3/22589\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency and resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency or resistance may result in osteomalacia by one of four mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired availability of vitamin D, secondary to inadequate dietary vitamin D, fat malabsorptive disorders,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of photoisomerization",
"     </li>",
"     <li>",
"      Impaired 25-hydroxylation of vitamin D in the liver to 25-OH vitamin D",
"     </li>",
"     <li>",
"      Impaired 1 alpha-hydroxylation of 25-hydroxyvitamin D in the kidney to 1,25(OH)2-vitamin D",
"     </li>",
"     <li>",
"      End organ insensitivity to vitamin D metabolites (hereditary vitamin D resistant rickets)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common cause of osteomalacia worldwide is dietary vitamin D deficiency combined with lack of sun exposure and, in the United States, gastrointestinal disease. Causes of vitamin D deficiency are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"     \"Causes of vitamin D deficiency and resistance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypophosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypophosphatemia due to increased urinary phosphate excretion is the predominant cause of the osteomalacia seen with the disorders of vitamin D metabolism. In these settings, low calcitriol levels lead to reduced calcium absorption and subsequent secondary hyperparathyroidism and urinary phosphate wasting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes of vitamin D deficiency and resistance\", section on 'Vitamin D dependent rickets type I'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary renal phosphate wasting syndromes can be inherited or acquired, either as an idiopathic disorder or in association with mesenchymal tumors (tumor-induced osteomalacia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/7\">",
"     7",
"    </a>",
"    ]. These disorders result from excessive circulating levels of the phosphaturic hormone, fibroblast growth factor 23 (FGF23), or other phosphaturic proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal phosphate wasting can also occur as part of an overall defect in proximal tubular transport in the Fanconi syndrome or in primary renal phosphate wasting syndromes. In adults, Fanconi syndrome is most commonly caused by multiple myeloma, which is often latent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/8\">",
"     8",
"    </a>",
"    ]. It has also been reported In HIV patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    , an antiretroviral drug, in patients with hepatitis B taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], and after exposure to heavy metals, such as cadmium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24760?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and toxicity of cadmium\", section on 'Tubular damage and dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link&amp;anchor=H4#H4\">",
"     \"Bone and calcium disorders in HIV-infected patients\", section on 'Effects of medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone disease in chronic kidney disease is due to a number of factors, including reduced formation of 1,25-dihydroxyvitamin D (calcitriol), metabolic acidosis, and administration of aluminum. Aluminum-containing antacids were the predominant cause of osteomalacia in this setting but are now much less commonly used, as other, safer phosphate binders are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia or rickets is most often seen with proximal (type 2) renal tubular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/11\">",
"     11",
"    </a>",
"    ]. In this setting, proximal phosphate wasting, increased calcium loss due to the metabolic acidosis, and secondary hyperparathyroidism may all contribute to the decrease in bone mineralization. Similar findings can occur with the acidosis seen after ureterosigmoidostomy.",
"   </p>",
"   <p>",
"    Although the association is controversial, osteomalacia has also been reported in patients with distal (type 1) renal tubular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one study, for example, two of seven patients with Sj&ouml;gren syndrome and distal RTA also had findings consistent with osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/12\">",
"     12",
"    </a>",
"    ]. Osteopenia and decreased bone formation have been described in this setting, with correction of acidosis increasing the bone formation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mineralization inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia is occasionally due to mineralization inhibitors. Included in this group are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bisphosphonates, which have a structure similar to native pyrophosphate, an important inhibitor of mineralization [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/14\">",
"       14",
"      </a>",
"      ]. However there are differences among the bisphosphonates in their potential to inhibit mineralization and cause osteomalacia. The circulating concentrations of the nitrogen-containing bisphosphonates currently in use (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      ) do not cause osteomalacia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link&amp;anchor=H6#H6\">",
"       \"Pharmacology of bisphosphonates\", section on 'Mineralization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aluminum, which, in addition to its role in chronic renal failure, has also been implicated in the osteomalacia that occurs in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      and amino acids in the form of casein hydrolysate [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluoride, which can cause osteomalacia when ingested in excessive quantities, as may occur in endemic fluorosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/17\">",
"       17",
"      </a>",
"      ] and with ingestion of fluoride toothpastes and certain teas [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypophosphatasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypophosphatasia is a rare, autosomal disease that is associated with low levels of alkaline phosphatase in serum and bone and the development of osteomalacia and severe periodontal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Four clinical forms have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/22\">",
"     22",
"    </a>",
"    ]. The disease may present in the perinatal period, when it is lethal, and in infancy, where initial development appears normal. However, rachitic deformities develop by age six months, and approximately 50 percent of affected patients die during infancy. Hypophosphatasia may also develop during childhood, with premature loss of deciduous teeth, delayed walking, and waddling gait. Symptoms may improve spontaneously after puberty and recur later in life. Adult hypophosphatasia is characterized by the presence of poorly healing, recurrent metatarsal stress fractures and bone pain (thighs and hips), as well as an increased incidence of chondrocalcinosis.",
"   </p>",
"   <p>",
"    The clinical features of the infantile form are reproduced in mice in which the genes for alkaline phosphatase have been deleted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/19\">",
"     19",
"    </a>",
"    ]. Approximately 224 mutations of the tissue-nonspecific isoenzyme of alkaline phosphatase have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/23\">",
"     23",
"    </a>",
"    ]. The severe forms are usually inherited as an autosomal recessive trait. The childhood and adult forms are autosomal dominant traits with variable penetrance and clinical expression. As an example, a mild autosomal dominant form has been described in which long bone bowing is detected in utero via ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/24\">",
"     24",
"    </a>",
"    ]. The skeletal defects spontaneously improved after birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Defective bone matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial osteomalacia is a rare generalized skeletal disorder of defective bone mineralization that presents with chronic axial skeletal pain, most often in the cervical spine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/25\">",
"     25",
"    </a>",
"    ]. Men are affected more than women, and it may be familial. Radiographic abnormalities (coarsened trabecular pattern) are seen in the spine and pelvis. Histopathologic studies of bone reveal osteoidosis and failure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    deposition. The pathogenesis is uncertain, but it may be caused by an osteoblast defect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibrogenesis imperfecta is a rare, sporadic, idiopathic disorder of defective bone matrix formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27494/abstract/27\">",
"     27",
"    </a>",
"    ]. Symptoms begin in adult life with pain, fractures and weakness. It affects the entire skeleton and is characterized pathologically by the absence of normal birefringent collagen fibrils. The cause is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inadequate calcium intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is suggestive evidence that inadequate intake of calcium may contribute to the development of osteomalacia. Among African children with rickets in whom exposure to sunlight was adequate, the intake of calcium, with or without vitamin D supplementation, was superior to vitamin D alone in improving the radiologic manifestations of rickets. Although the exact cause of rickets in these children was unclear, the adequate ingestion of calcium as well as vitamin D and phosphate in childhood appears essential for adequate skeletal formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Calcium deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169891\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteomalacia is a disorder of defective mineralization of newly formed osteoid at sites of bone turnover. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mineralization abnormalities occur as a consequence of inadequate calcium, phosphate,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alkaline phosphatase, or in the presence of abnormal bone matrix or direct inhibition of the mineralization process. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several different disorders cause osteomalacia. Severe vitamin D deficiency (25-hydroxyvitamin D &lt;10",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      [25",
"      <span class=\"nowrap\">",
"       nmol/L]),",
"      </span>",
"      secondary to inadequate dietary intake, lack of sun exposure, gastric bypass or malabsorption, is the most common cause of osteomalacia in adults. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiologic diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=see_link\">",
"       \"Causes of vitamin D deficiency and resistance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes include the hereditary or acquired disorders of phosphate wasting, type 2 renal tubular acidosis, and excessive exposure to inhibitors of bone mineralization (eg, aluminum toxicity, endemic fluorosis) (",
"      <a class=\"graphic graphic_table graphicRef70293 \" href=\"UTD.htm?22/3/22589\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiologic diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/1\">",
"      Ashwell M, Stone EM, Stolte H, et al. UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status. Br J Nutr 2010; 104:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/2\">",
"      Al-Shoha A, Qiu S, Palnitkar S, Rao DS. Osteomalacia with bone marrow fibrosis due to severe vitamin D deficiency after a gastrointestinal bypass operation for severe obesity. Endocr Pract 2009; 15:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/3\">",
"      Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 2010; 85:752.",
"     </a>",
"    </li>",
"    <li>",
"     Bone biopsy and histomorphometry in clinical practice. In: Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, Lippincott-Raven, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/5\">",
"      Russell JA. Osteomalacic myopathy. Muscle Nerve 1994; 17:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/6\">",
"      Reginster JY. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin 2005; 21:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/7\">",
"      Sommer S, Berndt T, Craig T, Kumar R. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 2007; 103:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/8\">",
"      Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/9\">",
"      Girgis CM, Wong T, Ngu MC, et al. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011; 45:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/10\">",
"      Kim du H, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab 2013; 31:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/11\">",
"      Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/12\">",
"      Fulop M, Mackay M. Renal tubular acidosis, Sj&ouml;gren syndrome, and bone disease. Arch Intern Med 2004; 164:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/13\">",
"      Disthabanchong S, Domrongkitchaiporn S, Sirikulchayanonta V, et al. Alteration of noncollagenous bone matrix proteins in distal renal tubular acidosis. Bone 2004; 35:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/14\">",
"      Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993; 342:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/15\">",
"      Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med 1983; 98:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/16\">",
"      Vargas JH, Klein GL, Ament ME, et al. Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content. Am J Clin Nutr 1988; 48:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/17\">",
"      Wang Y, Yin Y, Gilula LA, Wilson AJ. Endemic fluorosis of the skeleton: radiographic features in 127 patients. AJR Am J Roentgenol 1994; 162:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/18\">",
"      Kurland ES, Schulman RC, Zerwekh JE, et al. Recovery from skeletal fluorosis (an enigmatic, American case). J Bone Miner Res 2007; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     Mornet, E, Nunes, ME. Hypophosphatasia. In: GeneReviews, Pagon RA, Bird TC, Dolan CR, Stephens K (Eds), University of Washington, Seattle 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/20\">",
"      Mornet E. Hypophosphatasia. Best Pract Res Clin Rheumatol 2008; 22:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/21\">",
"      Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci 2010; 1192:190.",
"     </a>",
"    </li>",
"    <li>",
"     Whyte, MP. Enzyme defects and the skeleton. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Seventh Edition, Rosen CJ (Ed), The American Society of Bone and Mineral Research, Washington, DC 2008. p.454.",
"    </li>",
"    <li>",
"     file://www.sesep.uvsq.fr/03_hypo_mutations.php (Accessed on November 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/24\">",
"      Moore CA, Curry CJ, Henthorn PS, et al. Mild autosomal dominant hypophosphatasia: in utero presentation in two families. Am J Med Genet 1999; 86:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/25\">",
"      Whyte MP, Fallon MD, Murphy WA, Teitelbaum SL. Axial osteomalacia. Clinical, laboratory and genetic investigation of an affected mother and son. Am J Med 1981; 71:1041.",
"     </a>",
"    </li>",
"    <li>",
"     Whyte, MP. Sclerosing Bone Disorders. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Seventh Edition, Rosen CJ (Ed), American Society of Bone and Mineral Research, Washington, DC 2008. p.412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27494/abstract/27\">",
"      Lang R, Vignery AM, Jensen PS. Fibrogenesis imperfecta ossium with early onset: observations after 20 years of illness. Bone 1986; 7:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2045 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27494=[""].join("\n");
var outline_f26_54_27494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3169891\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3169360\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ETIOLOGIC DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mineralization inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypophosphatasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Defective bone matrix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inadequate calcium intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3169891\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2045|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/2/42018\" title=\"picture 1\">",
"      Osteoblasts and osteoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/32/520\" title=\"picture 2\">",
"      Low turnover osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2045|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/3/22589\" title=\"table 1\">",
"      Causes of osteomalacia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38184?source=related_link\">",
"      Causes of vitamin D deficiency and resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11416?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24760?source=related_link\">",
"      Epidemiology and toxicity of cadmium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_54_27495="Beau lines";
var content_f26_54_27495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62607%7EDERM%2F85705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62607%7EDERM%2F85705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Beau's lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse grooves representing Beau's lines are present on the nail plates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail plate detachment from the matrix area (onychomadesis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27495=[""].join("\n");
var outline_f26_54_27495=null;
var title_f26_54_27496="Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma";
var content_f26_54_27496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27496/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/54/27496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of Hodgkin lymphoma (formerly called Hodgkin's disease) has been established, subsequent therapy and prognosis are based upon the stage of the disease, as currently defined by the Cotswolds classification (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this discussion, early stage Hodgkin lymphoma is defined as those patients with stage I or II disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (Ie)",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIe)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with early (stage I-II) disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, large mediastinal adenopathy, and number of sites of involvement. Cooperative research groups have used varying definitions of favorable and unfavorable prognosis disease. These are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"     \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most commonly used definitions of unfavorable disease are those proposed by the European Organization for the Research and Treatment of Cancer (EORTC) and the German Hodgkin Study Group (GHSG):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EORTC defines the unfavorable prognostic group as patients with age over 50; with large mediastinal adenopathy; with an ESR of",
"      <span class=\"nowrap\">",
"       &ge;50/h",
"      </span>",
"      and no B symptoms (or with an ESR of &ge;30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      in those who have B symptoms);",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      four or more regions of involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The GHSG defines the unfavorable prognostic group as patients with more than two sites of disease; extranodal extension; mediastinal mass measuring one-third the maximum thoracic diameter or greater;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ESR &ge;50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      (&ge;30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      if B symptoms present) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of unfavorable prognosis stage I-II Hodgkin lymphoma will be reviewed here. The treatment of patients with favorable prognosis early stage disease or advanced stage disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6234375\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with HL must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. This evaluation is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172363\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of early stage, unfavorable prognosis Hodgkin lymphoma requires a careful balance between providing enough therapy to eradicate the tumor and avoiding unnecessary treatment that could result in excessive long-term treatment-related side effects. The preferred therapy for most patients is combination chemotherapy plus involved-field radiation therapy. Data from a number of studies indicate that radiation fields can be safely limited to involved regions (variably defined) in most combined modality programs.",
"   </p>",
"   <p>",
"    Despite the increasing availability of guidelines for the treatment of Hodgkin lymphoma, there must remain room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment. Some randomized studies have demonstrated worse survivals in treatment arms that have higher recurrence rates. Treatment should also be individualized when a particular approach might result in a higher risk of a serious late complication (eg, the use of large radiation fields and the risk of late breast cancer in young females and of lung cancer in smokers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Combined modality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality therapy comprised of combination chemotherapy plus involved-field radiation therapy is the standard treatment for patients with unfavorable prognosis stage I-II Hodgkin lymphoma. While the radiation therapy acts to control known sites of tumor, the chemotherapy is aimed at occult disease outside the radiation field. The combination of the two modalities allows for a decrease in the size of the radiation field used and the number of chemotherapy cycles given in an attempt to reduce long-term complications.",
"   </p>",
"   <p>",
"    There have been no randomized trials evaluating the optimal timing of chemotherapy and irradiation. In initial studies, many patients were treated with radiation therapy followed by adjuvant chemotherapy. In later studies, the advantages of initial treatment with chemotherapy became apparent. These included the opportunity to treat all involved and occult sites of disease at the outset, and the ability to use more restricted (and less toxic) radiation fields by taking advantage of tumor shrinkage secondary to chemotherapy. Some studies, which incorporated six months of conventional chemotherapy, used a \"split course\" or \"sandwich\" approach, with an initial three months of chemotherapy, followed by irradiation, and then completion of the chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Sequential completion of the full course of chemotherapy followed by radiation therapy has become standard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that have evaluated different chemotherapeutic regimens in unfavorable prognosis stage I-II disease generally have not identified important differences in overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) is usually considered the treatment of choice because of superior outcomes in trials of patients with advanced Hodgkin lymphoma and reduced late toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/5,9-11\">",
"     5,9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evolution of clinical trials to identify the best chemotherapy combination for these patients has paralleled studies to identify the best chemotherapy in advanced Hodgkin lymphoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early studies compared MOPP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) with MOPP-like combinations.",
"     </li>",
"     <li>",
"      Later trials compared MOPP or MOPP-like combinations with ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) in an attempt to both enhance efficacy and reduce toxicity by limiting exposure to alkylating agents.",
"     </li>",
"     <li>",
"      The most recent trials compared ABVD with more intense chemotherapy combinations such as escalated BEACOPP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The German Hodgkin Study Group (GHSG) and the EORTC have both conducted prospective clinical trials for unfavorable presentations of stage I-II HL in which combined modality programs utilizing ABVD were compared with programs utilizing BEACOPP (GHSG HD11 and EORTC H9U). It was the experience in both trials that toxicity was greater with BEACOPP and there was no difference in freedom from progression or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/12\">",
"     12",
"    </a>",
"    ]. Subsequent studies have investigated the incorporation of both ABVD and BEACOPP into the treatment of these patients.",
"   </p>",
"   <p>",
"    The GHSG HD11 Trial randomly assigned 1395 patients with unfavorable prognosis early-stage HL to receive one of the following four treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four cycles of ABVD followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of ABVD followed by 20 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of baseline BEACOPP followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of baseline BEACOPP followed by 20 Gy involved field radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligibility criteria for this trial included patients with at least one of the following risk factors: three or more sites of disease, extranodal extension, mediastinal mass greater than or equal to one-third the maximum thoracic diameter, and ESR greater than 50 (greater than 30 if B symptoms present). At a median follow-up of 7.5 years, overall survival was similar in all four treatment arms. Treatment with four cycles of ABVD followed by 30 Gy of involved field radiation therapy resulted in similar rates of progression-free survival and freedom from treatment failure when compared with either escalated BEACOPP strategy. Patients who received baseline BEACOPP had significantly higher rates of severe toxicity.",
"   </p>",
"   <p>",
"    The GHSG HD14 randomized trial found no benefit in terms of overall survival of two cycles of escalated BEACOPP followed by two cycles of ABVD when compared with four cycles of ABVD, both followed by 30 Gy involved field radiation therapy, in patients with unfavorable risk stage I-II HL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. After a median follow-up of 43 months, the use of escalated BEACOPP was associated with improved progression-free survival at five years (95 versus 89 percent), but no difference in overall survival at five years (97 percent, each) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients who received escalated BEACOPP had significantly higher rates of severe acute toxicity, but were less likely to require salvage with high dose therapy and autologous hematopoietic cell rescue. Longer follow-up is needed to evaluate for long-term toxicities.",
"   </p>",
"   <p>",
"    Less toxic chemotherapy regimens that have been effective in combined modality programs for favorable prognosis stage I-II Hodgkin lymphoma (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) do not appear to be effective in unfavorable prognosis or bulky disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. As an example, the EORTC H7U trial randomly assigned 316 patients with unfavorable prognosis early stage disease to receive combined modality therapy with involved field irradiation plus six cycles of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , vinblastine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (EBVP II) or",
"    <span class=\"nowrap\">",
"     MOPP/ABV",
"    </span>",
"    chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/17\">",
"     17",
"    </a>",
"    ]. The EBVP II regimen, given one time per month compared with two times per month for ABVD, was anticipated to be a less toxic regimen. However, the failure-free survival rate at three years was significantly lower with EBVP (72 versus 88 percent) and further entry into the trial was discontinued. At 10 years of follow-up, the event-free survival was significantly lower for EBVPII (68 versus 88 percent) as was the 10-year overall survival (79 versus 87 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Number of cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials have addressed the issue of the number of cycles of chemotherapy necessary in combined modality programs for unfavorable prognosis stage I-II disease.",
"   </p>",
"   <p>",
"    A three-arm EORTC H8U trial compared the hybrid",
"    <span class=\"nowrap\">",
"     MOPP/ABV",
"    </span>",
"    regimen for four versus six cycles and the radiation field size for involved versus extended fields in 996 patients with unfavorable prognosis early stage HL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/19\">",
"     19",
"    </a>",
"    ]. At 10 years of follow-up, there were no differences in failure-free or overall survival. Estimated five-year event-free survival rates were approximately 87 percent and 10-year overall survival estimates were approximately 86 percent. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiation field size'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The EORTC H9U trial randomly assigned patients with unfavorable prognosis stage I-II HL to receive one of three treatments: six cycles of ABVD, four cycles of ABVD, or four cycles of BEACOPP followed by 30 Gy involved-field radiation in all arms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/20\">",
"     20",
"    </a>",
"    ]. Preliminary results show similar four-year event-free and overall survival in all three arms, but increased toxicity with BEACOPP.",
"   </p>",
"   <p>",
"    In summary, these data suggest that patients with unfavorable disease by virtue of age, histology, number of sites of disease, or B symptoms perhaps can be treated adequately in combined modality programs with as few as four months of conventional chemotherapy. The randomized EORTC H8U trial using four cycles of chemotherapy provides the most complete evidence to date that four cycles of chemotherapy is sufficient when combined with radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radiation field size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials have addressed the question of radiation therapy volumes in combined modality programs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ]. The evidence from these randomized trials suggest that radiation fields can be safely limited to involved regions (variably defined) in most combined modality programs.",
"   </p>",
"   <p>",
"    The following is a survey of some of the randomized studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the HD8 trial from the German Hodgkin's Lymphoma Study Group, 1204 patients were randomly assigned to receive either involved or extended field irradiation after four cycles of",
"      <span class=\"nowrap\">",
"       COPP/ABVD",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. At a median observation period of 10 years, there was no difference in freedom from treatment failure or overall survival between the two treatment groups. Acute side effects (eg, leukopenia, thrombocytopenia, nausea, gastrointestinal and pharyngeal toxicity) were more frequent in those treated with extended field irradiation.",
"     </li>",
"     <li>",
"      In the EORTC-GELA H8 trial, 996 patients with unfavorable prognosis early stage HL were randomly assigned to one of three arms: six cycles of MOPP-ABV with involved-field radiotherapy, four cycles of MOPP-ABV with involved-field radiotherapy, or four cycles of MOPP-ABV with subtotal nodal radiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/19\">",
"       19",
"      </a>",
"      ]. Ten-year event-free and overall survival were equivalent between the three arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial studies of combined modality therapy generally used radiation doses that were similar to those used for radiation treatment alone (36 to 44 Gy). A later report combined patients with unfavorable disease from two studies of the German Hodgkin Study Group (GHSG), HD1 and HD5 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment consisted of two double cycles of",
"    <span class=\"nowrap\">",
"     COPP/ABVD",
"    </span>",
"    and extended field irradiation using three different doses: 20, 30, and 40 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/25\">",
"     25",
"    </a>",
"    ]. Bulky sites (&gt;5 cm in any axis) were always irradiated to 40 Gy. The four-year survivals were not different in the three groups (93, 94, and 88 percent, respectively).",
"   </p>",
"   <p>",
"    The interaction between radiation dose and chemotherapy regimen was best illustrated in the German Hodgkin Study Group (GHSG) HD11 Trial that randomly assigned 1395 patients with unfavorable prognosis early-stage HL to receive one of the following four treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four cycles of ABVD followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of ABVD followed by 20 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of baseline BEACOPP followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of baseline BEACOPP followed by 20 Gy involved field radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligibility criteria for this trial included patients with at least one of the following risk factors: three or more sites of disease, extranodal extension, mediastinal mass greater than or equal to one-third the maximum thoracic diameter, and ESR greater than 50 (greater than 30 if B symptoms present). At a median follow-up of 7.5 years, overall survival was similar in all four treatment arms. Treatment with four cycles of ABVD followed by 20 Gy of involved field radiation therapy resulted in inferior rates of progression-free survival and freedom from treatment failure when compared with the other three treatment arms, which all had similar rates to one another.",
"   </p>",
"   <p>",
"    The results of this trial suggest that four cycles of ABVD should be followed by 30 Gy involved field radiation therapy in patients with unfavorable prognosis early-stage Hodgkin lymphoma, as defined by the GHSG. If four cycles of baseline BEACOPP are administered, involved field radiation therapy with 20 Gy is likely sufficient. It is important to note that the results of this trial have not been segregated to evaluate only those patients who had large mediastinal adenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20118277\">",
"    <span class=\"h2\">",
"     Is there a role for chemotherapy alone?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of chemotherapy alone for the treatment of early stage HL is controversial. Nearly all of the trials evaluating chemotherapy with or without radiation therapy (RT) have been conducted in favorable prognosis patients. These trials have had a number of problems with design, patient accrual, as well as variations in the type of chemotherapy and field size of radiation therapy utilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Is there a role for chemotherapy alone?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, in the",
"    <span class=\"nowrap\">",
"     NCIC/ECOG",
"    </span>",
"    HD6 randomized trial, 405 patients with previously untreated stage IA or IIA",
"    <strong>",
"     non-bulky",
"    </strong>",
"    HL were randomly assigned treatment with four to six cycles of ABVD alone or to treatment that included 35 Gy RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/26\">",
"     26",
"    </a>",
"    ]. The RT arm consisted of two cycles of ABVD followed by sub-total nodal RT for patients with an unfavorable prognosis (n=276). At a median follow-up of 11.3 years, patients with unfavorable prognosis non-bulky HL treated with chemotherapy alone had a lower rate of freedom from disease progression (FFDP, 86 versus 94 percent) but a higher rate of overall survival (OS, 92 versus 82 percent) at 12 years. This improvement in survival was attributed to an increased rate of non-relapse mortality among patients treated with sub-total nodal RT.",
"   </p>",
"   <p>",
"    Unfortunately, this trial had a long time to completion of patient accrual such that the \"standard arm\", originally defined as extended-field irradiation, is currently no longer viewed as standard treatment. Modern RT utilizes lower doses directed at smaller fields and is presumed to result in less short-term and long-term toxicity.",
"   </p>",
"   <p>",
"    For most patients with unfavorable prognosis stage I-II HL, we recommend treatment with combined modality therapy rather than the use of chemotherapy or radiation therapy alone. This preference places a high value on the improved disease-free survival seen with this approach. It also assumes that the lower dose and smaller field size used in modern RT is associated with less long-term toxicity than higher dose larger field size treatment, without compromised efficacy. While not our preferred therapy, combination chemotherapy alone may be considered an alternative for patients with non-bulky early stage HL. Of importance, radiation is a critical component of the treatment of bulky early stage HL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172439\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for unfavorable prognosis stage I-II Hodgkin lymphoma apply to most disease presentations and patient populations. However, certain patient populations, such as pregnant women and older adults require special consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172446\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of Hodgkin lymphoma during pregnancy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=see_link\">",
"     \"Management of classical Hodgkin lymphoma during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172453\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that adult treatment protocols may be safe and provide comparable efficacy to pediatric protocols in the treatment of adolescents with HL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172460\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns over the ability of older adults (ie, over age 60 years) to tolerate intensive chemotherapy and radiation therapy. The management of lymphoma in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H33#H33\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that older adults should be initially treated with the same dosing and schedule as younger adults with adjustments made to future cycles according to tolerance. This is principally because the amount of chemotherapy administered in the initial treatment of Hodgkin lymphoma may affect overall survival. In a potentially curable disease such as Hodgkin lymphoma, it is especially important to treat all patients aggressively, even older individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98393918\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with HIV who develop HL is complicated by their immunocompromised state and also requires specific treatment for their HIV. As such, treatment of these patients is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506291#H1560506291\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5942098\">",
"    <span class=\"h2\">",
"     Infradiaphragmatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of patients with early stage Hodgkin lymphoma present with disease below the diaphragm. Infradiaphragmatic disease does not appear to be an independent predictor of poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27496/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, many of these patients will be categorized as having unfavorable prognosis early stage disease based upon other features of their disease (eg, high number of lymph nodes involved, B symptoms). We approach the treatment of patients with infradiaphragmatic disease in the same way that we approach patients with supradiaphragmatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172467\">",
"    <span class=\"h2\">",
"     Nodular lymphocyte predominant Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with the nodular lymphocyte predominant subtype of Hodgkin lymphoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=see_link\">",
"     \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35172474\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment of Hodgkin lymphoma, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse. The follow-up of patients with early (stage I-II) HL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link&amp;anchor=H20474802#H20474802\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Patient follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188580250\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the diagnosis of Hodgkin lymphoma (HL, formerly called Hodgkin's disease) has been established, subsequent therapy is based upon the stage of the disease, as currently defined by the Cotswolds classification (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"       \"Staging and prognosis of Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In this discussion, early stage Hodgkin lymphoma is defined as those patients with stage I or II disease (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage I &mdash; Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (Ie)",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIe)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with early disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Cooperative research groups have used varying definitions of favorable and unfavorable prognosis disease. In the US, patients who have B symptoms, large mediastinal adenopathy, or more than three regions of involvement are considered unfavorable. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with early stage unfavorable prognosis Hodgkin lymphoma, we recommend the use of combination chemotherapy plus involved-field radiation therapy rather than the use of combination chemotherapy or radiation therapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Specifically, we suggest ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) chemotherapy in combination with involved-field radiotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While not our preferred therapy, combination chemotherapy alone may be considered an alternative for patients with non-bulky early stage HL. Of importance, radiation is a critical component of the treatment of bulky early stage HL. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Combined modality therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Chemotherapy is given to maximal tumor response, as judged by computed tomography scan and positron emission tomography imaging, after which two additional cycles of consolidation chemotherapy are often given. Chemotherapy is followed by limited radiation therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"       \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients receiving combined modality treatment for early stage disease, we recommend involved-field irradiation rather than subtotal nodal irradiation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The involved fields may be modified slightly (eg, exclusion of high neck nodes or inferior mediastinum if uninvolved), but involved node treatment is not recommended at this time. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiation field size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients without bulky disease, radiation doses of 30 Gy appear to be adequate. A dose as low as 20 Gy is an option following BEACOPP chemotherapy. At present, bulky disease is still treated with 30 to 36 Gy. It is important to take advantage of tumor regression secondary to chemotherapy and to design treatment fields that conform to the width of the residual disease and not to the initial tumor volume. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiation dose'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The general treatment principles for unfavorable prognosis stage I-II Hodgkin lymphoma apply to most disease presentations and patient populations. However, certain patient populations, such as pregnant women and older adults require special consideration. (See",
"      <a class=\"local\" href=\"#H35172439\">",
"       'Special scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After completion of the initially planned treatment of Hodgkin lymphoma, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse or complications of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link&amp;anchor=H20474802#H20474802\">",
"       \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Patient follow-up'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/1\">",
"      Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992; 28A:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/2\">",
"      Engert A, Pl&uuml;tschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/3\">",
"      Hoppe RT, Portlock CS, Glatstein E, et al. Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease. Cancer 1979; 43:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/4\">",
"      Bonfante V, Santoro A, Viviani S, et al. Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer 1992; 29A:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/5\">",
"      Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/6\">",
"      Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     Hoppe RT, Horning SJ, Hancock SL, Rosenberg SA. Stanford clinical trials for Hodgkin's disease. In: Recent Results in Cancer Research, New Aspects in the Diagnosis and Treatment of Cancer, Springer-Verlag, Heidelberg 1989. p.182.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/8\">",
"      von Tresckow B, Pl&uuml;tschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol 2012; 30:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/9\">",
"      Advani RH, Horning SJ. Treatment of early-stage Hodgkin's disease. Semin Hematol 1999; 36:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/10\">",
"      Brusamolino E, Anselmo AP, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/11\">",
"      Bonfante V, Santoro A, Viviani S, et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992; 19:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/12\">",
"      Bauer K, Skoetz N, Monsef I, et al. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; :CD007941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/13\">",
"      Eich HT, Diehl V, G&ouml;rgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28:4199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/14\">",
"      Behringer K, Thielen I, Mueller H, et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012; 23:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/15\">",
"      Wasserman TH, Petroni GR, Millard FE, et al. Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051). Cancer 1999; 86:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/16\">",
"      Pavlovsky S, Schvartzman E, Lastiri F, et al. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol 1997; 15:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/17\">",
"      Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/18\">",
"      Pavone V, Ricardi U, Luminari S, et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol 2008; 19:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/19\">",
"      Ferm&eacute; C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/20\">",
"      Noordijk EM, Thomas J, Foerme MB, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (abstract). Proc Am Soc Clin Oncol 2005; 16:6505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/21\">",
"      Zittoun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985; 3:207.",
"     </a>",
"    </li>",
"    <li>",
"     Santoro A. Annual Conference of ECCO, Hamburg, Germany 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/23\">",
"      Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/24\">",
"      Sasse S, Klimm B, G&ouml;rgen H, et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol 2012; 23:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/25\">",
"      Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997; 15:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/26\">",
"      Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012; 366:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/27\">",
"      Eichenauer DA, Bredenfeld H, Haverkamp H, et al. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 2009; 27:6079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/28\">",
"      Darabi K, Sieber M, Chaitowitz M, et al. Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1,114 patients. Leuk Lymphoma 2005; 46:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27496/abstract/29\">",
"      Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. Haematologica 2006; 91:32.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4690 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27496=[""].join("\n");
var outline_f26_54_27496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6234375\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35172363\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Combined modality therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Number of cycles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radiation field size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20118277\">",
"      Is there a role for chemotherapy alone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35172439\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35172446\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35172453\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35172460\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98393918\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5942098\">",
"      Infradiaphragmatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35172467\">",
"      Nodular lymphocyte predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35172474\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188580250\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=related_link\">",
"      Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=related_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_54_27497="Valproate: Pediatric drug information";
var content_f26_54_27497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valproate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"    see \"Valproate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/35/11831?source=see_link\">",
"    see \"Valproate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Depacon&reg;;",
"     </li>",
"     <li>",
"      Depakene&reg;;",
"     </li>",
"     <li>",
"      Depakote&reg;;",
"     </li>",
"     <li>",
"      Depakote&reg; ER;",
"     </li>",
"     <li>",
"      Depakote&reg; Sprinkle;",
"     </li>",
"     <li>",
"      Stavzor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Divalproex&reg;;",
"     </li>",
"     <li>",
"      Apo-Valproic&reg;;",
"     </li>",
"     <li>",
"      Depakene&reg;;",
"     </li>",
"     <li>",
"      Dom-Divalproex;",
"     </li>",
"     <li>",
"      Epival&reg;;",
"     </li>",
"     <li>",
"      Mylan-Divalproex;",
"     </li>",
"     <li>",
"      Mylan-Valproic;",
"     </li>",
"     <li>",
"      Novo-Divalproex;",
"     </li>",
"     <li>",
"      Nu-Divalproex;",
"     </li>",
"     <li>",
"      PHL-Divalproex;",
"     </li>",
"     <li>",
"      PHL-Valproic Acid;",
"     </li>",
"     <li>",
"      PHL-Valproic Acid E.C.;",
"     </li>",
"     <li>",
"      PMS-Divalproex;",
"     </li>",
"     <li>",
"      PMS-Valproic Acid;",
"     </li>",
"     <li>",
"      PMS-Valproic Acid E.C.;",
"     </li>",
"     <li>",
"      ratio-Valproic;",
"     </li>",
"     <li>",
"      ratio-Valproic ECC;",
"     </li>",
"     <li>",
"      Rhoxal-valproic;",
"     </li>",
"     <li>",
"      Sandoz-Valproic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Infantile Spasms, Treatment",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to the increased risk of valproic acid and derivatives-associated hepatotoxicity, valproic acid and derivatives are not preferred agents for use in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Refractory seizures:",
"     </b>",
"     Limited data available: Oral: Loading dose: 20 mg/kg, followed by a maintenance dose of 5-10 mg/kg/dose every 12 hours; adjust dose according to serum concentrations; dosing based on a report of six neonates (GA: 30-41 weeks) that showed oral valproic acid effectively controlled seizure activity in five of six patients; however, therapy was discontinued in 50% of the patients due to hyperammonemia; frequent monitoring is recommended (Evans, 1998; Gal, 1988).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Refractory status epilepticus:",
"     </b>",
"     Limited data available: I.V.: Loading dose: 20-40 mg/kg followed by a continuous I.V. infusion of 5 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     was used in five neonates; once patients were seizure-free for 12 hours and no longer had seizure activity on EEG, the infusion rate was decreased every 2 hours by 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Uberall, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"      see \"Valproate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Use of Depakote&reg;-ER in pediatric patients &lt;10 years of age is not recommended; do not confuse Depakote&reg;-ER with Depakote&reg;.",
"     <b>",
"      Erroneous substitution of Depakote&reg; (delayed release tablets) for Depakote&reg;-ER has resulted in toxicities; only Depakote&reg;-ER is intended for once daily administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Depakote&reg;:  Adolescents &ge;16 years: Oral: 250 mg twice daily; adjust dose based on patient response; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stavzor&trade;: Children and Adolescents &ge;12 years: Oral: 250 mg twice daily; adjust dose based on patient response; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Depakote&reg; ER: Children and Adolescents &ge;12 years: Oral:  500 mg once daily for 7 days, then increase to 1000 mg once daily; adjust dose based on patient response; usual dosage range 500-1000 mg/day; dose should be individualized; if smaller dosage adjustments are needed, use Depakote&reg; delayed release tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Seizures disorders:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Due to the increased risk of valproic acid and derivatives-associated hepatotoxicity in patients &lt;2 years, valproic acid and derivatives are not preferred agents in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      General dosing:",
"     </i>",
"     Initial: 10-15 mg/kg/day in 1-3 divided doses; increase by 5-10 mg/kg/day at weekly intervals until seizures are controlled or side effects preclude further increases; daily doses &gt;250 mg should be given in divided doses; maintenance: 30-60 mg/kg/day in 2-3 divided doses; Depakote&reg; and Depakote&reg; Sprinkle can be given twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Children receiving more than 1 anticonvulsant (ie, polytherapy) may require doses up to 100 mg/kg/day in 3-4 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Simple and complex absence seizures:",
"     </i>",
"     Initial: 15 mg/kg/day in 1-3 divided doses; increase by 5-10 mg/kg/day at weekly intervals until seizures are controlled or side effects preclude further increases; daily doses &gt;250 mg should be given in divided doses; maintenance: 30-60 mg/kg/day in 2-3 divided doses; Depakote&reg; and Depakote&reg; Sprinkle can be given twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Conversion to Depakote&reg; ER from a stable dose of Depakote&reg;:",
"     </i>",
"     May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     C",
"     <i>",
"      onversion to monotherapy from adjunctive therapy:",
"     </i>",
"     The concomitant antiepileptic drug (AED) can be decreased by ~25% every 2 weeks; dosage reduction of the concomitant AED may begin when valproate or derivative therapy is initiated or 1-2 weeks following valproate or derivative initiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Parenteral: I.V.: Total daily I.V. dose is equivalent to the total daily oral dose; however, I.V. dose should be divided with a frequency of every 6 hours; if I.V. form is administered 2-3 times/day, close monitoring of trough concentrations is recommended; switch patients to oral product as soon as clinically possible as prolonged I.V. use has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Rectal: Dilute oral syrup 1:1 with water for use as a retention enema (Graves, 1987):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Loading dose: 17-20 mg/kg once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance: 10-15 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Status epilepticus; refractory:",
"     </b>",
"     Limited data available; optimal dose not established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Loading dose: Initial: 20-40 mg/kg has been reported in pediatric trials. In one retrospective study, an initial loading dose of 25 mg/kg was effective in stopping seizure activity within 20 minutes after the end of the infusion in all 18 patients treated for status epilepticus (Yu, 2003). A separate retrospective trial found a higher efficacy rate in pediatric patients who received an initial loading dose of 30-40 mg/kg (73.3%, N=15) compared to 20-30 mg/kg (46.2%, N=26) or &gt;40 mg/kg (40%, N=10) (Uberall, 2000). In an open-label, randomized comparative trial, an initial loading dose of 30 mg/kg was administered (n=20; age range: 7 months to 10 years of age; mean age: 3 years); a repeat bolus of 10 mg/kg could be administered if seizures were not controlled within 10 minutes; mean required dose: 37.5 &plusmn; 4.4 mg/kg; median required dose: 40 mg/kg (Mehta, 2007). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance dose: I.V. infusion: 5 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     after the loading dose was used in pediatric continuous I.V. infusion studies (Mehta, 2007; Uberall, 2000); once patients were seizure-free for 6 hours, the infusion rate was decreased by 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     every 2 hours (Mehta, 2007). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Rectal: Dilute oral syrup 1:1 with water for use as a retention enema (Snead, 1985):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Loading dose: 15-20 mg/kg once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance: 10-15 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Seizures: Note:",
"     </b>",
"     Administer doses &gt;250 mg/day in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Simple and complex absence seizure: Initial: 15 mg/kg/day; increase by 5-10 mg/kg/day at weekly intervals until therapeutic concentrations are achieved; maximum daily dose: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Complex partial seizure: Initial: 10-15 mg/kg/day; increase by 5-10 mg/kg/day at weekly intervals until therapeutic concentrations are achieved; maximum daily dose: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Regular release and delayed release formulations are usually given in 2-4 divided doses per day; extended release formulation (Depakote&reg; ER) is usually given once daily. In patients previously maintained on regular release valproic acid therapy (Depakene&reg;) who convert to delayed release divalproex sodium tablets (Depakote&reg;) or valproic acid capsules (Stavzor&trade;), the same daily dose and frequency as the regular release should be used; once therapy is stabilized, the frequency of Depakote&reg; or Stavzor&trade; may be adjusted to 2-3 times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Conversion to Depakote&reg; ER from a stable dose of Depakote&reg;: May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Conversion to monotherapy from adjunctive therapy: The concomitant antiepileptic drug (AED) can be decreased by ~25% every 2 weeks; dosage reduction of the concomitant AED may begin when the valproic acid or derivative is initiated or 1-2 weeks following valproic acid or derivative initiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Total daily I.V. dose should be equivalent to the total daily dose of the oral valproic acid or derivative; administer dose with the same frequency as oral products; switch patient to oral products as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Loading dose: I.V.: 15-45 mg/kg administered at &le;6 mg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: I.V. infusion: 1-4 mg/kg/hour; titrate dose as needed based upon patient response and evaluation of drug-drug interactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Mania:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Depakote&reg; tablet, Stavzor&trade;: Initial: 750 mg/day in divided doses; dose should be adjusted as rapidly as possible to desired clinical effect; maximum daily dose: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Depakote&reg; ER: Initial: 25 mg/kg/day given once daily; dose should be adjusted as rapidly as possible to desired clinical effect; maximum daily dose: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Depakote&reg; tablet, Stavzor&trade;: 250 mg twice daily; adjust dose based on patient response, maximum daily dose: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Depakote&reg; ER: 500 mg once daily for 7 days, then increase to 1000 mg once daily; adjust dose based on patient response; usual dosage range 500-1000 mg/day; dose should be individualized; if smaller dosage adjustments are needed, use Depakote&reg; delayed release tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment required; however, protein binding is reduced in patients with renal impairment; monitoring",
"     <b>",
"      only",
"     </b>",
"     total valproate serum concentrations may be misleading.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Valproic acid and derivatives are contraindicated in patients with hepatic disease or significant hepatic dysfunction. Potentially fatal hepatotoxicity may occur with valproic acid or derivative use. Clearance is decreased in patients with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction of valproate. Free concentrations of valproate may be elevated while total concentrations appear normal; therefore, monitoring",
"     <b>",
"      only",
"     </b>",
"     total valproate concentrations may be misleading.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 250 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakene&reg;: 250 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stavzor&trade;: 125 mg, 250 mg, 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sprinkle, oral: 125 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; Sprinkle: 125 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as valproate sodium [preservative free]: 100 mg/mL (5 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depacon&reg;: 100 mg/mL (5 mL) [contains edetate disodium; strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as valproate sodium: 250 mg/5 mL (5 mL, 473 mL, 480 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as valproate sodium: 250 mg/5 mL (5 mL, 10 mL, 473 mL, 480 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakene&reg;: 250 mg/5 mL (473 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 125 mg [strength expressed as valproic acid], 250 mg [strength expressed as valproic acid], 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg;: 125 mg, 250 mg, 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 250 mg [strength expressed as valproic acid], 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; ER: 250 mg, 500 mg [strength expressed as valproic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes delayed release capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F16335927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Stavzor&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food to decrease adverse GI effects; do not administer with carbonated drinks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; ER: Swallow whole; do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; sprinkle capsules: May be swallowed whole or may mix contents of capsule with semisolid food (eg, applesauce, pudding, mashed potatoes) and swallow immediately; do not crush or chew sprinkle beads; do not store drug food mixture for later use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakene&reg; capsule, Stavzor&trade;: Swallow whole; do not break, crush, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer recommendations: Dilute dose with at least 50 mL (in adults) of D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR; infuse over 60 minutes; maximum infusion rate: 20 mg/minute;",
"     <b>",
"      Note:",
"     </b>",
"     Rapid infusions may be associated with an increase in adverse effects; infusions of &le;15 mg/kg administered over 5-10 minutes (1.5-3 mg/kg/minute); were generally well tolerated (Ramsay, 2003). In pediatric patients, an infusion rate of 1.5-3 mg/kg/minute has been recommended (Brophy, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapid I.V. loading doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: Optimal administration rate is not established. One retrospective pediatric study administered loading doses of 25 mg/kg at a rate of ~3 mg/kg/minute (Yu, 2003). However, a prospective study administered 30 mg/kg of the drug diluted 1:1 in NS over 2-5 minutes (Mehta, 2007). Another retrospective study administered loading doses at a slightly faster rate: 20-40 mg/kg diluted 1:1 with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W administered over 1-5 minutes (Uberall, 2000). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: The European Federation of Neurological Societies (EFNS) recommends maximum administration rates of 6 mg/kg/minute (Meierkord, 2006).",
"     <b>",
"      Note:",
"     </b>",
"     In two adult studies, the drug was administered undiluted at rates as high as 10 mg/kg/minute (Limdi, 2007) and 500 mg/minute (Limdi, 2005). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Dilute oral solution or syrup 1:1 with an equal volume of water prior to administration (Graves, 1987)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depakote&reg; tablets and Depakene&reg; solution: Store below 30&deg;C (86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depakote&reg; Sprinkles: Store below 25&deg;C (77&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depakote&reg; ER tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depakene&reg; capsules: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depacon&reg; injection: Store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Stable for at least 24 hours at room temperature when diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR and stored in glass or polyvinyl chloride bags.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavzor&trade; capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release capsules and syrup (Depakene&reg;): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, monotherapy and adjunctive therapy of simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved in pediatric patients (age not specified) and adults]; has also been used to treat mixed seizure types, myoclonic and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms; oral syrup has also been used rectally for treatment of seizure disorders when oral route is not available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Delayed release capsules (Stavzor&trade;): Monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved pediatric patients (age not specified) and adults]; monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults); prophylaxis of migraine headaches (FDA approved in ages &ge;12 years and adults); treatment of manic episodes of bipolar disorders (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Delayed release tablets (Depakote&reg;): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved in pediatric patients (age not specified) and adults]; prophylaxis of migraine headaches (FDA approved in ages &ge;16 years and adults); treatment of manic episodes of bipolar disorders (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release tablets (Depakote ER&reg;): Monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved in pediatric patients (age not specified) and adults]; monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults); prophylaxis of migraine headaches (FDA approved in ages &ge;12 years and adults); treatment of manic episodes of bipolar disorders (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sprinkle capsules (Depakote&reg;): Adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved in pediatric patients (age not specified) and adults]; monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults); has also been used to treat mixed seizure types, myoclonic and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Injection (Depacon&reg;): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, monotherapy and adjunctive therapy of simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved in pediatric patients (age not specified) and adults]; has also been used to treat mixed seizure types, myoclonic and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms.",
"     <b>",
"      Note:",
"     </b>",
"     Parenteral formulation is indicated for patients in whom oral administration of valproic acid or derivatives is temporarily not feasible; has also been used in patients with absence status epileptics.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depakene&reg; may be confused with Depakote&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depakote&reg; may be confused with Depakene&reg;, Depakote&reg; ER, Senokot&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depakote&reg; ER may be confused with divalproex enteric coated",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valproate sodium may be confused with vecuronium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F233074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Arrhythmia, chest pain, edema, facial edema, hyper-/hypotension, orthostatic hypotension, palpitation, peripheral edema, tachycardia, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, ataxia, chills, confusion, coordination abnormal, depression catatonia, dizziness, dyskinesia, emotional lability, euphoria, fever, hallucination, headache, hypoesthesia, insomnia, malaise, nervousness, pain, personality disorder, somnolence, speech disorder, tardive dyskinesia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Alopecia, bruising, discoid lupus erythematosus, dry skin, furunculosis, petechia, pruritus, rash, seborrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Amenorrhea, dysmenorrhea, hypoproteinemia, metrorrhagia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, constipation, diarrhea, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, gastroenteritis, glossitis, gum hemorrhage, hematemesis, incontinence, mouth ulceration, nausea, pancreatitis, periodontal abscess, stomatitis, taste perversion, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Cystitis, dysuria, urinary frequency, urinary incontinence, vaginal hemorrhage, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Thrombocytopenia (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site inflammation, injection site pain, injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthralgia, arthrosis, back pain, dysarthria, hypertonia, hypokinesia, leg cramps. myalgia, myasthenia, neck pain, neck rigidity, paresthesia, reflex increased, tremor, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Abnormal vision, amblyopia, blurred vision, conjunctivitis, diplopia, dry eyes, eye pain, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Deafness, ear pain, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, pharyngitis, pneumonia, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, hiccups, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggression, agranulocytosis, allergic reaction, anaphylaxis, anemia, aplastic anemia, asterixis, behavioral deterioration, bilirubin increased, bleeding time altered, bone marrow suppression, bone pain, bradycardia, breast enlargement, cutaneous vasculitis, carnitine decreased, cerebral atrophy (reversible), coma (rare), dementia, encephalopathy (rare), enuresis, eosinophilia, erythema multiforme, Fanconi-like syndrome (rare, in children), galactorrhea, hematoma formation, hemorrhage, hepatic failure, hepatotoxicity, hostility, hyperactivity, hyperammonemia, hyperammonemic encephalopathy (in patients with UCD), hyperglycinemia, hypersensitivity reactions (severe, with multiorgan dysfunction), hypofibrinogenemia, hyponatremia, hypothermia, inappropriate ADH secretion, intermittent porphyria, LDH increased, leukopenia, lupus, lymphocytosis, macrocytosis, menstrual irregularities, pancytopenia parkinsonism, parotid gland swelling, photosensitivity, platelet aggregation inhibited, polycystic ovary disease (rare), psychosis, seeing \"spots before the eyes,\" Stevens-Johnson syndrome, suicidal behavior/ideation, thyroid function tests abnormal, toxic epidermal necrolysis (rare), urinary tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to valproic acid, a derivative, or any component; hepatic disease or significant hepatic dysfunction; urea cycle disorders (UCD)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valproic acid and derivatives may stimulate the replication of HIV and CMV",
"     <i>",
"      in vitro",
"     </i>",
"     ; clinical effects are unknown. CNS depression may occur with use of valproic acid or a derivative. Patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving). Effects with other sedative drugs or ethanol may be potentiated. Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; valproic acid and derivatives should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Patients treated for bipolar disorder should be monitored closely for clinical worsening or suicidality; prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic failure resulting in death may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; neonates, infants and children &lt;2 years of age are at considerably increased risk, especially those on anticonvulsant polytherapy, with congenital metabolic disorders, with severe seizure disorders and mental retardation, or with organic brain disease; monitor patients closely for appearance of malaise, loss of seizure control, weakness, facial edema, anorexia, jaundice and vomiting; hepatotoxicity has been reported during the first 6 months of therapy; monitor liver enzymes prior to therapy and at frequent intervals, especially during the first 6 months; discontinue valproic acid and derivatives if hepatotoxicity occurs; hepatic dysfunction may progress despite discontinuing treatment. Although carnitine has been used for the management of valproic acid and derivatives overdose and toxicity, the role of prophylactic carnitine supplementation is unclear (Freeman, 1994; Raskind, 2000). A case of a fatal hepatotoxic reaction has been reported in a child receiving valproic acid despite carnitine supplementation (Murphy, 1993). A valproic acid-associated Reye's-like syndrome has also been reported (Hilmas, 2000).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of life-threatening pancreatitis (including fatalities) have been reported in children and adults",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; pancreatitis may be hemorrhagic and rapidly progress to death; onset has occurred shortly after starting therapy and after several years of treatment; monitor patients closely for nausea, vomiting, anorexia, and abdominal pain and evaluate promptly; discontinue valproic acid and derivatives if pancreatitis occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Dose-related thrombocytopenia, inhibition of platelet aggregation, and bleeding may occur; risk of thrombocytopenia increases significantly with serum valproic acid concentrations &ge;110 mcg/mL in females or &ge;135 mcg/mL in males; in some cases, platelet counts may normalize with continued treatment; however, reduce dose or discontinue drug if patient develops evidence of hemorrhage, bruising, or a disorder of hemostasis/coagulation. Evaluate platelet counts prior to initiating therapy and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Parenteral valproate is not recommended for the prophylaxis of post-traumatic seizures in patients with acute head trauma; study results for this use suggested increased mortality with parenteral valproate compared to parenteral phenytoin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hyperammonemic encephalopathy, which may be fatal, has been reported following initiation of valproic acid and derivatives and may be present with normal transaminase concentrations. Ammonia concentrations should be measured in patients who develop symptoms of hyperammonemic encephalopathy during therapy with valproic acid or a derivative: Unexplained lethargy and vomiting, changes in mental status, or in patients who present with hypothermia; discontinue therapy if ammonia concentrations are increased and evaluate for possible urea cycle disorder (UCD), particularly ornithine transcarbamylase deficiency. Valproic acid and derivatives are contraindicated in patients with UCD. Before valproic acid or a derivative is started, evaluation for UCD should be considered in patients with 1) a history of unexplained coma or encephalopathy, encephalopathy associated with a protein load, unexplained mental retardation, pregnancy or postpartum encephalopathy, or history of increased plasma ammonia or glutamine; 2) cyclical vomiting and lethargy, episodic extreme irritability, ataxia, low BUN, or protein avoidance; 3) family history of UCD or family history of unexplained infant deaths (especially males); or 4) other signs and symptoms of UCD. Concurrent use of valproic acid or a derivative with topiramate may result in hyperammonemia with or without encephalopathy; use with caution in patients with inborn errors of metabolism or decreased hepatic mitochondrial activity; these patients may be at increased risk. Hyperammonemia should also be considered when patients present with hypothermia. Hypothermia (unintentional drop in core body temperature to &lt;35&deg;C/95&deg;F) has been reported with valproic acid and derivatives; hypothermia may or may not be associated with hyperammonemia; may also occur with concomitant topiramate therapy following topiramate initiation or dosage increase. Some patients may have asymptomatic elevations of ammonia; monitor closely and consider discontinuation if elevations persist.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Congenital malformations such as neural tube defects (eg, spina bifida), craniofacial defects, cardiovascular malformations, and anomalies of other body systems may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use in women of childbearing potential requires that benefits of use in the mother be weighed against the potential risk to the fetus, especially when used for conditions not associated with permanent injury or risk of death (eg, migraine). Maternal use of valproic acid or a derivative during pregnancy may result in clotting abnormalities or hepatic failure in the newborn.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Multiorgan hypersensitivity reactions have been rarely reported in adults and pediatric patients in association with initiation of valproic acid and derivatives; at least one death has been reported; patient may present with fever and rash in association with symptoms of organ system dysfunction [eg, lymphadenopathy, hepatitis, abnormalities in liver function tests, hematologic abnormalities (eosinophilia, neutropenia, thrombocytopenia), pruritus, oliguria, nephritis, arthralgia, asthenia]; valproic acid and derivatives should be discontinued in patients suspected of having multiorgan hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED-treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs, informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For valproic acid:",
"     <b>",
"      Substrate",
"     </b>",
"     (minor) of CYP2A6, 2B6, 2C9, 2C19, 2E1;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), 2C19 (weak), 2D6 (weak), 3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15578418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Valproic Acid may decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Valproic Acid. Valproic Acid may decrease the serum concentration of CarBAMazepine. Carbamazepine-Epoxide concentrations might increase, offsetting the decreases in the parent compound.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbapenems: May decrease the serum concentration of Valproic Acid. Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlorproMAZINE: May increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Valproic Acid. Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Valproic Acid may increase the serum concentration of Ethosuximide. Ethosuximide may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of Valproic Acid. Management: In patients receiving valproic acid, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce valproic acid dose by 20%. Monitor for increased valproate concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Fosphenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: May increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Valproic Acid may enhance the adverse/toxic effect of LamoTRIgine. Valproic Acid may increase the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LORazepam: Valproic Acid may decrease the metabolism of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Valproic Acid may decrease the serum concentration of OXcarbazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: Valproic Acid may increase the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Phenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Valproic Acid may decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, would be decreased. Primidone may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Valproic Acid may enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Valproic Acid may increase the serum concentration of Rufinamide.  Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temozolomide: Valproic Acid may enhance the adverse/toxic effect of Temozolomide. Valproic Acid may increase the serum concentration of Temozolomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May enhance the adverse/toxic effect of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Valproic Acid may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vorinostat: Valproic Acid may enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Valproic Acid may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary carnitine requirements may be increased; food may decrease the rate but not the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: May cause teratogenic effects such as neural tube defects (eg, spina bifida).",
"     </b>",
"     Teratogenic effects have been reported in animals and humans. Valproic acid crosses the placenta. Neural tube, cardiac, facial (characteristic pattern of dysmorphic facial features), skeletal, multiple other defects reported. Epilepsy itself, number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy. Information from the North American Antiepileptic Drug Pregnancy Registry notes a fourfold increase in congenital malformations with exposure to valproic acid monotherapy during the 1st trimester of pregnancy when compared to monotherapy with other antiepileptic drugs (AED). The risk of neural tube defects is ~1% to 2% (general population risk estimated to be 0.14% to 0.2%). The effect of folic acid supplementation to decrease this risk is unknown, however, folic acid supplementation is recommended for all women contemplating pregnancy. An information sheet describing the teratogenic potential is available from the manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Nonteratogenic effects have also been reported. Afibrinogenemia leading to fatal hemorrhage and hepatotoxicity have been noted in case reports of infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to valproic acid. Developmental delay, autism and/or autism spectrum disorder have also been reported. In a prospective cohort study conducted in the U.S. and the United Kingdom, a lower Differential Ability Scale ([D.A.S.]; a battery of tests which measure cognitive development in children) score was observed in children 3 years of age with prenatal exposure to valproate compared to children with prenatal exposure to other antiepileptics (lamotrigine, carbamazepine, or phenytoin). Use in women of childbearing potential requires that benefits of use in mother be weighed against the potential risk to fetus, especially when used for conditions not associated with permanent injury or risk of death (eg, migraine).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to valproic acid during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes (prior to therapy and at frequent intervals, especially during the first 6 months), bilirubin, serum ammonia (with symptoms of lethargy, mental status change), CBC with platelets (prior to initiation and periodically during therapy), serum concentrations, PT/PTT (especially prior to surgery); signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, trough concentrations should be used to assess adequacy of therapy; peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). Additional patient-specific factors must be taken into consideration when interpreting drug concentrations, including indication, age, clinical response, pregnancy status, adherence, comorbidities, adverse effects, and concomitant medications (Patsalos, 2008; Reed, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Seizure disorder:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Therapeutic: 50-100 mcg/mL (SI: 350-690 micromoles/L); the relationship between plasma concentration and therapeutic response is not well documented; some patients may require lower concentrations to achieve therapeutic effect, and others may require higher concentration, but have a higher risk of toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic: &gt;100-150 mcg/mL (SI: &gt;690-1040 micromoles/L); probability of thrombocytopenia increases with total valproate concentrations &ge;110 mcg/mL (SI: &ge;760 micromoles/L) in females or &ge;135 mcg/mL (SI: &ge;930 micromoles/L) in males",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Seizure control may improve at concentrations &gt;100 mcg/mL (SI: &gt;690 micromoles/L), but toxicity may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mania: Therapeutic trough: 50-125 mcg/mL (SI: 350-860 micromoles/L); risk of toxicity increases at concentrations &gt;125 mcg/mL (SI: 875 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes increased availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, to brain neurons or may enhance the action of GABA or mimic its action at postsynaptic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 90% (concentration dependent); free fraction: ~10% at serum concentration of at 40 mcg/mL and ~18.5% at 130 mcg/mL; decreased protein binding in neonates and patients with renal impairment or chronic hepatic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into CSF at concentrations similar to unbound concentration in plasma (ie, &sim;10% of total plasma concentration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Total valproate: 11 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Free valproate: 92 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via glucuronide conjugation (30% to 50% of administered dose) and 40% via mitochondrial beta-oxidation; other oxidative metabolic pathways occur to a lesser extent. The relationship between dose and total valproate concentration is nonlinear; concentration does not increase proportionally with the dose, but increases to a lesser extent due to saturable plasma protein binding. The kinetics of unbound drug are linear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: All products, except Depakote&reg;-ER, are equivalent to I.V.",
"     <b>",
"      Depakote&reg;-ER tablets are not equivalent to Depakote&reg; delayed release tablets and are not interchangeable",
"     </b>",
"     ; mean bioavailability of Depakote&reg;-ER tablets is 89%, relative to Depakote&reg; delayed release tablets. In pediatric patients 10-17 years of age, once-daily administration of Depakote&reg;-ER produced valproate plasma concentration-time profiles similar to adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Increased with liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns (exposed to VPA",
"     <i>",
"      in utero",
"     </i>",
"     ): 30-60 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates 1st week of life: 40-45 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates &lt;10 days: 10-67 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &gt;2 months: 7-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 2-14 years: 9 hours (Range: 3.5-20 hours) (Cloyd, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 9-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Depakote &reg; tablet and sprinkle capsules: ~4 hours; Depakote&reg; ER: 4-17 hours; Stavzor&trade;: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 1-3 hours (Graves, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: End of the infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (30% to 50% as glucuronide conjugate, &lt;3% as unchanged drug); faster clearance in children who receive other antiepileptic drugs and those who are younger; age and polytherapy explain 80% of interpatient variability in total clearance; children &gt;10 years of age have pharmacokinetic parameters similar to adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis reduces valproate concentrations by ~20%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/35/11831?source=see_link\">",
"      see \"Valproate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol. May cause drowsiness and impair ability to perform activities requiring mental alertness and physical coordination. Do not discontinue abruptly (an increase in seizure activity may result). Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician of depressive symptoms or thoughts of suicide or self-harm. Notify physician if nausea, vomiting, unexplained lethargy, change in mental status, general feeling of weakness, loss of appetite, abdominal pain, yellow skin, bleeding, or easy bruising occur. Report fever associated with rash, swelling, or other organ system involvement immediately to physician. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute intoxications: Naloxone may reverse the CNS depressant effects but may also block the action of other anticonvulsants; carnitine may reduce the ammonia concentration",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brophy GM, Bell R, Claassen J, et al, \"Guidelines for the Evaluation and Management of Status Epilepticus,\"",
"      <i>",
"       Neurocrit Care",
"      </i>",
"      , 2012, 17(1):3-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/22528274/pubmed\" id=\"22528274\" target=\"_blank\">",
"        22528274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cloyd JC, Fischer JH, Kriel RL, et al, &ldquo;Valproic Acid Pharmacokinetics in Children. IV. Effects of Age and Antiepileptic Drugs on Protein Binding and Intrinsic Clearance,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 53(1):22-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/8422737 /pubmed\" id=\"8422737 \" target=\"_blank\">",
"        8422737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cloyd JC, Kriel RL, Fischer JH, et al, &ldquo;Pharmacokinetics of Valproic Acid in Children: I. Multiple Antiepileptic Drug Therapy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1983, 33(2):185-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/6401848/pubmed\" id=\"6401848\" target=\"_blank\">",
"        6401848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dreifuss FE, Santilli N, Langer DH, et al, &ldquo;Valproic Acid Hepatic Fatalities: A Retrospective Review,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1987, 37(3):379-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/3102998/pubmed\" id=\"3102998\" target=\"_blank\">",
"        3102998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Evans D and Levene M, \"Neonatal Seizures,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1998, 78(1):70-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/9536846/pubmed\" id=\"9536846\" target=\"_blank\">",
"        9536846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman JM, Vining EP, Cost S, et al, &ldquo;Does Carnitine Administration Improve the Symptoms Attributed to Anticonvulsant Medications?: A Double-Blinded, Crossover Study,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 93(6 Pt 1):893-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/8190572/pubmed\" id=\"8190572\" target=\"_blank\">",
"        8190572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gal P, Oles KS, Gilman JT, et al, \"Valproic Acid Efficacy, Toxicity, and Pharmacokinetics in Neonates With Intractable Seizures,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1988, 38(3):467-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/3126410/pubmed\" id=\"3126410\" target=\"_blank\">",
"        3126410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Go CY, Mackay MT, Weiss SK, et al, \"Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(24):1974-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/22689735/pubmed\" id=\"22689735\" target=\"_blank\">",
"        22689735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al, \"ILAE Treatment Guidelines: Evidence-Based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2006, 47(7):1094-120.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/16886973/pubmed\" id=\"16886973\" target=\"_blank\">",
"        16886973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graves NM and Kriel RL, \"Rectal Administration of Antiepileptic Drugs in Children,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1987, 3(6):321-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/3334021/pubmed\" id=\"3334021\" target=\"_blank\">",
"        3334021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilmas E and Lee CK, &ldquo;Valproic Acid-Related Reye's-Like Syndrome,&rdquo;",
"      <i>",
"       The Journal of Pediatric Pharmacy Practice",
"      </i>",
"      , 2000, 5(3):149-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Limdi NA, Knowlton RK, Cofield SS, et al, \"Safety of Rapid Intravenous Loading of Valproate,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(3):478-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/17319914/pubmed\" id=\"17319914\" target=\"_blank\">",
"        17319914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Limdi NA, Shimpi AV, Faught E, et al, \"Efficacy of Rapid IV Administration of Valproic Acid for Status Epilepticus,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 64(2):353-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/15668440/pubmed\" id=\"15668440\" target=\"_blank\">",
"        15668440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehta V, Singhi P, and Singhi S, \"Intravenous Sodium Valproate Versus Diazepam Infusion for the Control of Refractory Status Epilepticus in Children: A Randomized Controlled Trial,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2007, 22(10):1191-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/17940245/pubmed\" id=\"17940245\" target=\"_blank\">",
"        17940245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, \"EFNS Guideline on the Management of Status Epilepticus,\"",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2006, 13(5):445-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/16722966/pubmed\" id=\"16722966\" target=\"_blank\">",
"        16722966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy JV, Groover RV and Hodge C, &ldquo;Hepatotoxic Effects in a Child Receiving Valproate and Carnitine,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(2):318-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/8345435 /pubmed\" id=\"8345435 \" target=\"_blank\">",
"        8345435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patsalos PN, Berry DJ, Bourgeois BF, et al, &ldquo;Antiepileptic Drugs -- Best Practice Guidelines for Therapeutic Drug Monitoring: A Position Paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2008, 49(7):1239-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/18397299/pubmed\" id=\"18397299\" target=\"_blank\">",
"        18397299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsay RE, Cantrell D, Collins SD, et al, \"Safety and Tolerance of Rapidly Infused Depacon. A Randomized Trial in Subjects With Epilepsy,\"",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 2003, 52(3):189-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/12536052/pubmed\" id=\"12536052\" target=\"_blank\">",
"        12536052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskind JY and El-Chaar GM, \"The Role of Carnitine Supplementation During Valproic Acid Therapy,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(5):630-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/10852092/pubmed\" id=\"10852092\" target=\"_blank\">",
"        10852092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed RC and Dutta S, &ldquo;Does It Really Matter When a Blood Sample for Valproic Acid Concentration Is Taken Following Once-Daily Administration of Divalproex-ER?&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2006, 28(3):413-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/16778728/pubmed\" id=\"16778728\" target=\"_blank\">",
"        16778728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snead OC 3rd and Miles MV, \"Treatment of Status Epilepticus in Children With Rectal Sodium Valproate,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 106(2):323-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/3918159/pubmed\" id=\"3918159\" target=\"_blank\">",
"        3918159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uberall MA, Trollmann R, Wunsiedler U, et al, \"Intravenous Valproate in Pediatric Epilepsy Patients With Refractory Status Epilepticus,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2000, 54(11):2188-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/10851397/pubmed\" id=\"10851397\" target=\"_blank\">",
"        10851397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yu KT, Mills S, Thompson N, et al, \"Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2003, 44(5):724-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/54/27497/abstract-text/12752474/pubmed\" id=\"12752474\" target=\"_blank\">",
"        12752474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12873 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27497=[""].join("\n");
var outline_f26_54_27497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708868\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233020\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233021\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055961\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445214\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055952\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232991\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232975\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335927\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055966\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055956\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055965\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233074\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055969\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055951\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055950\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15578418\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055972\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232987\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233002\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055960\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055964\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055949\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055968\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055958\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055970\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12873|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=related_link\">",
"      Valproate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/35/11831?source=related_link\">",
"      Valproate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_54_27498="Treatment of Lyme disease";
var content_f26_54_27498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Lyme disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27498/contributors\">",
"     Linden Hu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27498/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/54/27498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/54/27498/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/54/27498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is the most common tick-borne disease in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/1\">",
"     1",
"    </a>",
"    ]. It is a spirochetal infection caused by Borrelia species (B. burgdorferi in the United States, and primarily B. afzelii and B. garinii in Europe and Asia) and is transmitted by the bite of infected Ixodes ricinus complex ticks. Lyme disease can involve the skin, joints, nervous system, and heart.",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America and the American Academy of Neurology published practice guidelines for the treatment of Lyme disease in the United States in 2006 and 2007, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The treatment of Lyme disease in the United States will be reviewed here and the recommendations largely reflect these guidelines. Antibiotic regimens for the treatment of B. burgdorferi infection are summarized in the following table (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, clinical manifestations, and diagnosis of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of other tick-borne diseases is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=see_link\">",
"     \"Treatment of Rocky Mountain spotted fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26533?source=see_link\">",
"     \"Southern tick-associated rash illness (STARI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL STAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Lyme disease can generally be divided into three phases: early localized, early disseminated, and late disease (",
"    <a class=\"graphic graphic_table graphicRef72018 \" href=\"UTD.htm?39/7/40060\">",
"     table 2",
"    </a>",
"    ). However, the clinical features of each stage can overlap and some patients present in a later stage of Lyme disease without a history of prior signs or symptoms suggestive of earlier Lyme disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early localized disease is characterized by the appearance of the characteristic skin lesion, erythema migrans (EM), with or without constitutional symptoms (",
"      <a class=\"graphic graphic_picture graphicRef81270 \" href=\"UTD.htm?10/10/10400\">",
"       picture 1",
"      </a>",
"      ). EM usually occurs within one month following the tick bite.",
"     </li>",
"     <li>",
"      Early disseminated disease is characterized by multiple erythema migrans lesions (that typically occur days to weeks after infection)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac findings (that typically occur weeks to months after infection). Some of these patients have no history of antecedent early localized Lyme disease.",
"     </li>",
"     <li>",
"      Late Lyme disease is typically associated with intermittent or persistent arthritis involving one or a few large joints, especially the knee (sometimes preceded by migratory arthralgias);",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      certain rare neurologic problems, primarily a subtle encephalopathy or polyneuropathy. Late Lyme disease may develop months to a few years after the initial infection. Arthritis may be the presenting manifestation of the disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS FOR TICK BITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis following a tick bite by an Ixodes tick is indicated in some cases. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of a tick bite for possible Lyme disease\", section on 'Efficacy and rationale'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EARLY DISEASE (ERYTHEMA MIGRANS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema migrans is the primary manifestation of early (also called early localized) Lyme disease. It usually occurs a few days to one month following an Ixodes tick bite.",
"   </p>",
"   <p>",
"    Erythema migrans may be accompanied by fever and regional lymphadenopathy (each present in a minority of patients) and a variety of more subjective symptoms such as fatigue, malaise, lethargy, headache, neck stiffness, myalgias, and arthralgias (",
"    <a class=\"graphic graphic_table graphicRef72018 \" href=\"UTD.htm?39/7/40060\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. These influenza-like signs and symptoms infrequently occur in the absence of erythema migrans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Early localized disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spirochetal dissemination often occurs during the first days or weeks of infection while the initial erythema migrans lesion is still present. This may result in multiple erythema migrans lesions. Unless the patient also has objective findings suggesting neurologic or cardiac involvement, the treatment is the same as that for patients with a single lesion. The goal of therapy is to shorten the duration of the signs and symptoms of early disease and to reduce the risk of development of late Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials have demonstrated the efficacy of antimicrobial therapy in patients with erythema migrans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. Different antibiotic regimens were used in these trials, and the criteria used to define treatment success and failure varied.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective trial, 72 adults with erythema migrans were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      (500 mg three times daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily) each for 21 days [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4\">",
"       4",
"      </a>",
"      ]. Both regimens were equally effective, and none of the patients experienced progression of disease.",
"     </li>",
"     <li>",
"      A randomized multicenter trial of 232 patients with erythema migrans compared treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil (500 mg twice daily) to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg three times daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/5\">",
"       5",
"      </a>",
"      ]. Each regimen was given for 20 days and both were equally effective (clinical success in 90 versus 95 percent, respectively). Similar efficacy was noted in another randomized trial comparing these drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/6\">",
"       6",
"      </a>",
"      ]. The only major complication at one month posttreatment was Lyme arthritis in one patient who was treated with cefuroxime axetil; there were no other cases of Lyme arthritis at later follow-up.",
"     </li>",
"     <li>",
"      A randomized multicenter trial of 246 adult patients with erythema migrans found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg three times daily for 20 days) was superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (500 mg once daily for seven days) in producing complete resolution of signs and symptoms of infection at the end of therapy (88 versus 76 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial from Europe of 88 patients with erythema migrans showed that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (500 mg on day one, followed by 250 daily for four days) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily for 14 days) resulted in similar outcomes (96 versus 83 percent clinical success, respectively, which was a non-significant difference) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/11\">",
"       11",
"      </a>",
"      ]. Erythema migrans in Europe is usually caused by B. afzelii, which does not usually disseminate. Therefore, doxycycline and azithromycin may give equivalent results in that setting. However, in the United States, strains of B. burgdorferi usually do disseminate. In studies done in the United States, azithromycin was not as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (and therefore presumably not as effective as doxycycline) in the treatment early Lyme disease with hematogenous dissemination [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with early disseminated disease, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      is as effective as intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      . This was illustrated in an open-label controlled trial of 140 patients with early disseminated Lyme disease without meningitis who were randomly assigned to oral doxycycline (100 mg twice daily for 21 days) or ceftriaxone (2 g once daily intravenously or intramuscularly for 14 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/10\">",
"       10",
"      </a>",
"      ]. Disseminated disease was considered present if the patient had at least one of the following findings: more than one erythema migrans lesion, carditis manifested by heart block, neurologic abnormalities (facial nerve palsy or radiculitis of less than three months' duration), and acute large joint arthritis.",
"      <br/>",
"      <br/>",
"      The rate of clinical cure was the same in both groups (88 and 85 percent, respectively), while treatment failure occurred in one patient in each group. Persistent symptoms at the last follow-up, usually mild arthralgias, were less common with doxycycline (14 versus 27 percent), but this difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of antimicrobial agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the results of the above trials, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil have equivalent efficacy for the treatment of early Lyme disease. We recommend treatment with one of these drugs in patients with erythema migrans. Doxycycline is often used because it is effective in treating a potential coinfecting agent, Anaplasma phagocytophilum. Of the oral agents commonly used to treat Lyme disease, doxycycline has the best penetration into the central nervous system. Doxycycline is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for children under the age of eight years or for pregnant or lactating women. However, a single treatment course of doxycycline may be given to children younger than eight years in whom the alternate agents are contraindicated.",
"   </p>",
"   <p>",
"    In the United States, macrolides (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) are",
"    <strong>",
"     not",
"    </strong>",
"    recommended as first-line therapy for erythema migrans because they are less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/7\">",
"     7",
"    </a>",
"    ] and presumably the other first-line drugs. Some strains of B. burgdorferi exhibit resistance to macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Macrolides should be reserved for the minority of patients who are intolerant of amoxicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. Early studies with macrolides used only short (5 to 7 day) courses of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. It is unknown whether longer courses (14 to 21 days) are as effective as other therapies. Patients treated with a macrolide should be followed closely for evidence of an inadequate response such as persistent objective findings of Lyme disease, relapse after apparent clinical response, or evolution into a later stage of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First-generation cephalosporins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ) are",
"    <strong>",
"     not",
"    </strong>",
"    effective for Lyme disease and should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,14,15\">",
"     2,14,15",
"    </a>",
"    ]. In some cases, erythema migrans may be confused with cellulitis. When this occurs in a Lyme-endemic area, it is appropriate to treat a skin rash with an antibiotic that will treat both cellulitis pathogens and Lyme disease (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Possible coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Lyme disease in endemic areas may be coinfected with the other infections transmitted by Ixodes ticks: Anaplasma phagocytophilum, which causes human granulocytic anaplasmosis (previously called human granulocytic ehrlichiosis), and Babesia microti in the United States; and tick-borne encephalitis virus in Europe. In different studies of patients with Lyme disease in the United States, the reported prevalence of coinfection has ranged from 4 to 28 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Coinfection with other tick-borne pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the three drugs used for erythema migrans, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is effective against A. phagocytophilum, which causes human granulocytic anaplasmosis (HGA, previously called human granulocytic ehrlichiosis). Thus, in patients infected in areas endemic for both Lyme disease and HGA, we suggest treatment with doxycycline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the antibiotics used for Lyme disease is effective in the treatment of Babesia microti or tick-borne encephalitis virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link&amp;anchor=H16#H16\">",
"     \"Arthropod-borne encephalitides\", section on 'Tick-borne encephalitis virus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of antibiotics for early Lyme disease is as follows (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      &ndash; 100 mg orally twice daily for adults; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily (maximum 100 mg dose) for children &ge;8 years of age",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      &ndash; 500 mg three times daily for adults; 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses (maximum 500 mg per dose) for children",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       Cefuroxime",
"      </a>",
"      axetil &ndash; 500 mg twice daily for adults; 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses (maximum 500 mg per dose) for children",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the trials of therapy for erythema migrans used a treatment duration of 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. However, other trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    have shown that 10 to 14 days of therapy is as effective as more prolonged therapy in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For erythema migrans in the United States, the best data about the relationship between treatment duration and efficacy come from a randomized double-blind trial in which 180 patients with erythema migrans were assigned to one of three treatment groups: 10 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ; one dose of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    followed by 10 days of doxycycline; or 20 days of doxycycline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/17\">",
"     17",
"    </a>",
"    ]. Efficacy was assessed at 20 days and at 3, 12, and 30 months. There was no significant difference in outcome among the groups at any of the follow-up time points. One of 61 patients who received 10 days of doxycycline developed Lyme meningitis at day 18 and was successfully treated with two weeks of intravenous ceftriaxone.",
"   </p>",
"   <p>",
"    Duration of therapy for erythema migrans has also been evaluated in Europe, where most cases of erythema migrans are caused by B. afzelii, which does not usually disseminate (in contrast to B. burgdorferi infection in the United States). A trial evaluated the efficacy of 10 versus 15 days of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in 225 patients in Slovenia who had a single erythema migrans lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/16\">",
"     16",
"    </a>",
"    ]. Twelve months after enrollment, 85 of 91 patients (93 percent) who received 15 days of therapy had a complete response without sequelae, compared with 79 of 86 patients (91 percent) who received 10 days of therapy. At six months, the frequency of non-specific symptoms was similar in the two groups. These results show that for patients in Europe with a solitary erythema migrans lesion, a 10 day regimen of oral doxycycline is non-inferior to a 15 day regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In keeping with the 2006 Infectious Diseases Society of America guidelines, we recommend treatment of patients with erythema migrans with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Dosing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is generally preferred because it is also effective against A. phagocytophilum, which causes human granulocytic anaplasmosis. However, doxycycline should be avoided in pregnant women and children under eight years of age;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    is preferred in such patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    should be given for 10 to 21 days;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil should be given for 14 to 21 days, depending upon the response to therapy (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Dosing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with early disseminated disease, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for 21 days in patients who have no neurologic disease other than isolated facial nerve palsy (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/10\">",
"     10",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    is as effective, it has the disadvantage of requiring parenteral administration. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Acute neurologic manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with early Lyme disease who receive appropriate antibiotic therapy have complete resolution of the signs and symptoms of infection within 20 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/7\">",
"     7",
"    </a>",
"    ] and, in one trial, erythema migrans and its associated symptoms resolved in a mean of five to six days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients who are more systemically ill at the beginning of treatment may take longer to recover [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, appropriate dosing and duration of therapy early in the course (ie, within weeks of the onset of infection) prevents progression to late Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have mild subjective symptoms, such as headache, musculoskeletal pain, arthralgia, or fatigue, that persist for weeks to months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. These subjective findings often resolve spontaneously, usually within six months, without further antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4\">",
"     4",
"    </a>",
"    ]; they are not due to ongoing active Lyme disease. More prolonged subjective symptoms after appropriate antibiotic therapy has been called the post-Lyme disease syndrome. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with persistent objective findings, particularly high fever, may be coinfected with the other tick-borne infections transmitted by Ixodes ticks. Investigation for coinfection with these agents is warranted if the initial antimicrobial does not have activity against these pathogens. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Possible coinfection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Almost all patients who have a satisfactory response to antibiotic therapy do well over the long term. Among 201 patients in two randomized treatment trials who had a satisfactory outcome at one month and were evaluable at one year posttreatment, 190 (95 percent) continued to have a satisfactory outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Jarisch-Herxheimer reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral therapy for Lyme disease is generally well tolerated. However, up to 15 percent of patients with early Lyme disease, particularly those with multiple erythema migrans lesions, experience a transient worsening of symptoms during the first 24 hours of therapy, consistent with a Jarisch-Herxheimer reaction, which is due to the host immune response to antigens released by dying organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/5,8,20\">",
"     5,8,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EARLY DISSEMINATED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early disseminated Lyme disease is characterized by neurologic and cardiac manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with acute neurologic manifestations of Lyme disease often require intravenous antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Early disseminated disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meningitis, cranial neuropathy (particularly facial nerve palsy), and sensory or motor radiculoneuropathy, alone or in combination, are the most common manifestations of acute neurologic Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for patients with acute neurologic manifestations are based upon small case series from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/21\">",
"     21",
"    </a>",
"    ], as well as prospective open-label trials, most of which were conducted in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/22-27\">",
"     22-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose intravenous penicillin was associated with more rapid resolution of symptoms in 12 patients compared with historical controls treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      were as effective as penicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/26,27\">",
"       26,27",
"      </a>",
"      ] and the two cephalosporins had equal efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Europe, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and intravenous penicillin were equally effective as all patients responded [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In Europe, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is routinely used as it has been demonstrated to be effective for early disseminated Lyme disease with neurologic manifestations, including meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/22,28,29\">",
"     22,28,29",
"    </a>",
"    ]. This practice has not been studied in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although there are differences among the strains prevalent in Europe and the United States, there are no in vitro data to suggest differences in susceptibility to doxycycline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Doxycycline has moderately good penetration into the CSF, which was shown in one study to be comparable to that of intravenous penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/32\">",
"     32",
"    </a>",
"    ]. Doxycycline has oral bioavailability &gt;98 percent, making oral dosing equivalent to intravenous dosing. The use of doxycycline for neurologic Lyme disease in the United States is not currently recommended, but may be considered in select cases in which intravenous therapy is not practical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Facial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with isolated facial nerve palsy can be treated successfully with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/20,23,33\">",
"     20,23,33",
"    </a>",
"    ]. Antibiotic therapy does not have a major impact on the outcome of facial palsy. However, treatment is recommended to prevent other complications of disseminated Lyme disease. The majority of patients with Lyme facial palsy recover fully (median time to recovery in one study was 26 days with a range of 1 to 270 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/33\">",
"     33",
"    </a>",
"    ]. The prognosis is worse for patients with bilateral facial palsy compared with unilateral palsy.",
"   </p>",
"   <p>",
"    In a prospective, nonrandomized study of 29 patients in Sweden with Lyme facial nerve palsy and meningitis, treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 to 400 mg daily) for 9 to 17 days was associated with clinical recovery in 26 patients (90 percent) within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/23\">",
"     23",
"    </a>",
"    ]. Post-treatment cerebrospinal fluid (CSF) examination showed a marked improvement in cell and protein levels as compared to pretreatment CSF analysis in all patients.",
"   </p>",
"   <p>",
"    Despite these findings, the 2006 Infectious Diseases Society of America (IDSA) guidelines and the 2007 American Academy of Neurology (AAN) practice parameter recommend parenteral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or an alternate agent when abnormal CSF findings are present [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the United States, only patients with isolated facial nerve palsy in the absence of abnormal cerebrospinal fluid findings, meningitis, or radiculoneuritis, are treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (as opposed to parenteral ceftriaxone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , or penicillin).",
"   </p>",
"   <p>",
"    Given that headache and neck stiffness are frequent complaints in patients with early Lyme disease, the decision of whether to perform a lumbar puncture in patients with facial nerve palsy who also have these features can be challenging. The IDSA recommends lumbar puncture in patients with facial nerve palsy in whom there is a strong clinical suspicion of central nervous system involvement (eg, severe or prolonged headache or nuchal rigidity) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no established role for glucocorticoids as an adjunctive therapy for the neurologic manifestations of Lyme disease, although there has been interest in using these agents in an attempt to decrease the duration or severity of facial nerve palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/3\">",
"     3",
"    </a>",
"    ]. A retrospective review of 101 patients with facial nerve palsy due to Lyme disease found no difference in outcomes between those who received glucocorticoids and those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, in a study that followed patients with Lyme disease for 10 to 20 years, no benefit was afforded by glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Recommended antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous antibiotic therapy is indicated for acute neurologic manifestations of Lyme disease with the exception of isolated facial palsy, which can usually be treated with oral antibiotics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute neurologic disease &mdash; Recommended antibiotic regimens for acute neurologic disease include (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (in adults: 2 g intravenously once daily; in children: 50 to 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once daily, maximum dose 2 g) OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      (in adults: 2 g intravenously every eight hours; in children: 150 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously per day divided in three doses, maximum dose 6 g per day) OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      (in adults: 18 to 24 million units per day intravenously divided into 6 daily doses; in children: 200,000 to 400,000",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per day divided into 6 daily doses, maximum 18 to 24 million units per day)",
"      <br/>",
"      <br/>",
"      Adults and children &ge;8 years who are intolerant of beta-lactam antibiotics should receive oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (in adults: 200 to 400 mg per day in two divided doses; in children: 4 to 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses, maximum, 100 to 200 mg per dose). The higher dose of doxycycline may not be well tolerated. In addition, some patients with neuroborreliosis in the United States require intravenous antibiotic therapy for successful treatment of the infection. Desensitization to a cephalosporin or penicillin may be considered in patients with a history of an IgE-mediated (anaphylactic) reaction to these agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"       \"Allergy to penicillins\", section on 'Desensitization'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"       \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated facial nerve palsy &mdash; For isolated facial nerve palsy, the preferred agent is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg orally twice daily for adults; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily (maximum 100 mg per dose) for children &ge;8 years of age. However, doxycycline is not recommended for children under the age of eight years or for pregnant or lactating women. A single treatment course of doxycycline may be given to children younger than eight years in whom the alternate agents are contraindicated.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      may be effective alternatives to doxycycline, but this has not been demonstrated in clinical trials. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Intravenous antibiotic therapy may be warranted for facial palsy if the CSF findings include a pleocytosis, elevated protein concentration, or increased concentration of specific anti-B. burgdorferi antibodies when compared with serum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment investigated for neurologic Lyme disease has ranged from 10 to 28 days for meningitis or radiculopathy and from 14 to 21 days for facial nerve palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. In Europe, a 10 to 14 day course was associated with excellent outcomes in two randomized, controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006 Infectious Diseases Society of America (IDSA) guidelines and the 2007 American Academy of Neurology (AAN) practice parameter recommend a treatment duration of 14 days for acute neurologic manifestations of Lyme disease, although any duration within the above range (10 to 28 days) is considered acceptable by the IDSA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no studies to help guide length of therapy within the range suggested by the guidelines. Furthermore, there are no diagnostic tests that can determine clearance of infection or predict the success of therapy. Resolution of neurological symptoms is often delayed and persistence of symptoms is not necessarily indicative of treatment failure. In the United States, many practitioners favor using longer courses of antibiotics (21 to 28 days), particularly for those with evidence of more severe infection. A 14-day course is adequate in selected patients with mild to moderate signs and symptoms.",
"   </p>",
"   <p>",
"    Patients with isolated facial nerve palsy are generally treated for 14 to 28 days. We prefer a 28-day course if the facial nerve palsy has not resolved within 14 days. A 14-day course is generally adequate if the facial nerve palsy is of short duration. In some patients, facial nerve palsy persists for months regardless of the duration or route of administration (oral versus intravenous) of antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Carditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac manifestations (eg, atrioventricular block and myopericarditis) that may be seen in early disseminated Lyme disease are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"     \"Lyme carditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Lyme carditis are treated to prevent later complications of Lyme disease and to shorten the duration of the cardiac manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of the potential for life-threatening complications, patients who are symptomatic (eg, syncope, dyspnea, or chest pain), have second or third degree atrioventricular (AV) block, or have first degree AV block with a markedly prolonged PR interval (&ge;300 milliseconds) should be hospitalized, monitored with cardiac telemetry, and treated with intravenous antibiotics (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89981358\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;No comparative trials have been performed to identify the optimal antibiotic regimen for Lyme carditis or to confirm that outcomes are improved with initial treatment with intravenous antibiotics compared with oral antibiotics. Supportive data come from case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89981365\">",
"    <span class=\"h4\">",
"     IV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, patients who are symptomatic (eg, syncope, dyspnea, or chest pain), have second or third degree atrioventricular (AV) block, or have first degree AV block with a markedly prolonged PR interval (&ge;300 milliseconds) should be hospitalized, monitored with cardiac telemetry, and treated with intravenous antibiotics (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. When IV therapy is required, the drug of choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily in adults; 50 to 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily in children), but appropriate alternatives include IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ). Desensitization to ceftriaxone, cefotaxime, or penicillin should be considered in patients who require IV therapy but have a history of an IgE-mediated (anaphylactic) reaction to these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"     \"Allergy to penicillins\", section on 'Desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IV antibiotics should be continued until high-grade AV block has resolved and the PR interval has become less than 300 milliseconds. The patient may then be switched to oral therapy to complete of a 21 to 28 day course. Appropriate oral antibiotics include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil, although doxycycline should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children &lt;8 years of age or in pregnant women (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89981372\">",
"    <span class=\"h4\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with early disseminated disease and first-degree AV block with a PR interval &lt;300 milliseconds who are not admitted to the hospital can be treated initially with oral therapy (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who are admitted to the hospital for cardiac monitoring should be treated initially with IV antibiotics, but should be switched to an oral regimen prior to or at the time of hospital discharge. The total duration of therapy is 21 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link&amp;anchor=H89979848#H89979848\">",
"     \"Lyme carditis\", section on 'IV therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The drugs of choice for oral therapy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil, although doxycycline should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children &lt;8 years of age or in pregnant women (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89981379\">",
"    <span class=\"h3\">",
"     Telemetry and pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are symptomatic (eg, syncope, dyspnea, or chest pain), have second or third degree atrioventricular (AV) block, or have first degree AV block with a markedly prolonged PR interval (&ge;300 milliseconds) require hospitalization for close monitoring with cardiac telemetry and intravenous antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. Once the PR interval is &lt;300 milliseconds, monitoring with telemetry is usually continued for an additional 24 to 48 hours.",
"   </p>",
"   <p>",
"    Patients with severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic AV block may require a temporary pacemaker; the indications for pacing are the same as in other causes of heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/37\">",
"     37",
"    </a>",
"    ]. Since AV block caused by Lyme disease is usually short-lived, temporary pacing is often required only for several days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=see_link&amp;anchor=H16#H16\">",
"     \"Temporary cardiac pacing\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link&amp;anchor=H4#H4\">",
"     \"Lyme carditis\", section on 'Atrioventricular conduction abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LATE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis and, in rare instances, subtle neurologic findings, are the major manifestations of late Lyme disease in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Late disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first weeks to months of Lyme disease, patients can have migratory musculoskeletal pain, including pain in joints, muscles, tendons, bursae, and bone, usually in one or a few locations at a time. Later in the infection, untreated patients in the United States often develop frank arthritis, which is usually manifested as marked swelling and pain in one or a few large joints, especially the knee. Without antibiotic treatment, Lyme arthritis typically is characterized by intermittent attacks. Patients may have persistent fatigue between attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"     \"Musculoskeletal manifestations of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have prominent musculoskeletal symptoms in association with erythema migrans are treated in the same way as those with isolated erythema migrans (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Recommendations'",
"    </a>",
"    above). In contrast, those with Lyme arthritis (joint swelling and pain) are treated for a longer duration.",
"   </p>",
"   <p>",
"    Lyme arthritis can usually be treated successfully with a one-month course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    . However, there are patients who require intravenous antibiotic therapy for successful treatment of the infection, and uncommonly, patients may have persistent synovitis despite treatment with oral and intravenous antibiotic therapy. Such patients are usually treated with antiinflammatory therapy or arthroscopic synovectomy. The treatment of Lyme arthritis in the absence of neurologic findings is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ). If a person has had previous attacks of arthritis but is currently asymptomatic or has persistent fatigue and has not previously received antibiotic therapy, it is reasonable to treat with a one month course of appropriate oral antibiotics to prevent subsequent attacks of arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link&amp;anchor=H12#H12\">",
"     \"Musculoskeletal manifestations of Lyme disease\", section on 'Management of Lyme arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with both Lyme arthritis and neurologic manifestations should be treated according to the recommendations for neurologic disease (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Late neurologic findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Late neurologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of late neurologic Lyme disease include a subtle encephalopathy, peripheral neuropathy, and encephalomyelitis. These are all extremely rare manifestations of late Lyme disease, even in untreated patients. With appropriate antibiotic therapy for early Lyme disease, late neurologic findings have almost disappeared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for patients with late neurologic manifestations of Lyme disease acquired in the United States are based upon small studies. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 23 patients with late Lyme disease with arthritis or neurologic findings were randomly assigned to intravenous penicillin (20 million units per day for 10 days) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (4 g per day for 14 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/26\">",
"       26",
"      </a>",
"      ]. Among the 13 patients who received ceftriaxone, only one did not respond (ongoing fatigue and memory problems); in contrast, 5 of the 10 patients who received penicillin failed therapy. In a subsequent phase of the study that compared 2 g to 4 g of ceftriaxone for 14 days, the outcomes were similar in both groups as 13 percent of patients had persistent symptoms.",
"     </li>",
"     <li>",
"      An uncontrolled study evaluated 27 patients with Lyme encephalopathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polyneuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/38\">",
"       38",
"      </a>",
"      ]. The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for two weeks) led to improvement in 17 (63 percent), improvement followed by relapse in six (22 percent), and no response in four (15 percent). The cerebrospinal fluid (CSF) findings generally improved after antibiotic therapy regardless of the clinical response, whereas objective neurologic tests improved primarily in patients with symptomatic improvement.",
"      <br/>",
"      <br/>",
"      The same researchers subsequently performed another uncontrolled study in which 18 consecutive patients with Lyme encephalopathy were treated with intravenous ceftriaxone (2 g once daily for 30 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/39\">",
"       39",
"      </a>",
"      ]. The mean duration of encephalopathy was 24 months and the mean interval between erythema migrans and the development of encephalopathy was 72 months. At six months following treatment, 14 of the 15 patients (93 percent) had improvement in symptoms. In addition, verbal memory scores were significantly higher and CSF protein levels were significantly lower in the 10 patients who had follow-up analysis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      therapy given for two to four weeks may also be effective in children with late neurologic Lyme disease. This was illustrated in observational study of five such children; gradual improvement in symptoms occurred in all four of the children in whom follow-up information was available [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From the above data, it is not possible to determine if a 30 day course of antibiotic therapy is superior to a 14 day course for late neurologic Lyme disease. The Infectious Diseases Society of America and the American Academy of Neurology recommend a treatment duration of 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations are the same for both the early and late neurologic manifestations of Lyme disease (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Recommendations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Duration of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2252074771\">",
"    <span class=\"h2\">",
"     Acrodermatitis chronica atrophicans",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, acrodermatitis chronica atrophicans is a cutaneous manifestation of late Lyme disease that may appear years following primary infection. This condition is primarily due to B. afzelii and has not been described convincingly in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Acrodermatitis chronica atrophicans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trials have addressed the efficacy of treatment of acrodermatitis chronica atrophicans. Patients are typically treated with the same oral regimens that are used for early Lyme disease (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil) for a duration of 21 days (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"     2",
"    </a>",
"    ]. Doxycycline is avoided in children &lt;8 years of age and pregnant women. In observational studies, oral or parenteral antibiotics appeared to result in improvement in pain and swelling, diminution of fibrous nodules, and gradual fading of the lesion over two to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,41,42\">",
"     2,41,42",
"    </a>",
"    ]. Areas of atrophy usually persist, and the progression of associated neuropathy is probably halted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who develop Lyme disease during pregnancy should be treated according to their disease manifestations. One limitation is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    should be avoided during pregnancy. There is no evidence that Lyme disease during pregnancy causes harm to the developing fetus. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2353682622\">",
"    <span class=\"h1\">",
"     REINFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may be infected with Lyme disease more than once [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Reinfection is most often identified by the development of a new EM rash in a patient with a history of Lyme disease. The diagnosis of reinfection may be difficult in patients with disseminated disease without EM because there are no established criteria for diagnosing reinfection based on serologic testing.",
"   </p>",
"   <p>",
"    Patients with Lyme arthritis are relatively resistant to reinfection with B. burgdorferi after antibiotic therapy, whereas those treated during earlier stages typically are not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Reinfection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H27411375#H27411375\">",
"     \"Diagnosis of Lyme disease\", section on 'Reinfection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26552?source=see_link&amp;anchor=H490085#H490085\">",
"     \"Immunopathogenesis of Lyme disease\", section on 'Antibody response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without EM, careful evaluation of the history and risk factors for reinfection must be performed to ensure that there are no other causes for the symptoms, and that symptoms are not part of the natural history of the original B. burgdorferi infection. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If a diagnosis of reinfection has been established, patients should be treated with the same antibiotic regimen as would be recommended for a primary infection, and the specific regimen depends upon the clinical presentation as discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POST-LYME DISEASE SYNDROME AND CHRONIC LYME DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with appropriate antibiotics as defined above is successful in the majority of patients with each of the stages of Lyme disease. Most patients with early disease have complete resolution of the signs and symptoms of infection within 20 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In contrast, the response to therapy is often slower in patients with late disease, particularly late neurologic manifestations. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Response to therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Late disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Microbiologic treatment failure does occur, but is rare. No strain of B. burgdorferi has been described that is resistant to the primary antibiotics recommended for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/13,45\">",
"     13,45",
"    </a>",
"    ]. Poor absorption or noncompliance with treatment is a more likely explanation for treatment failure than intrinsic resistance of the organism.",
"   </p>",
"   <p>",
"    When the term \"treatment failure\" is used, it usually refers to symptoms that have persisted or recurred. Some Lyme disease patients have mild subjective symptoms, such as headache, musculoskeletal pain, arthralgia, lethargy, cognitive complaints,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fatigue, that persist for weeks to months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4,6-8,46\">",
"     4,6-8,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations have addressed the issue of persistent symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of patients with early Lyme disease, mild subjective symptoms were noted after treatment in almost one-half of patients and correlated significantly with the severity of the initial illness [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/8\">",
"       8",
"      </a>",
"      ]. Extending antibiotic therapy from 10 to 20 days had no effect on the frequency of these symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/8\">",
"       8",
"      </a>",
"      ], which typically resolve within six months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort study, patients with a history of treated Lyme disease were significantly more likely than controls to report joint pains (odds ratio [OR] 2.1) and memory impairment (OR 1.9) at a mean of six years after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/46\">",
"       46",
"      </a>",
"      ]. However, physical examination and neurocognitive studies performed in a blinded fashion showed no differences between cases and controls.",
"     </li>",
"     <li>",
"      Randomized controlled trials of repeat antimicrobial therapy in patients with persistent symptoms after recommended therapy for Lyme disease have",
"      <strong>",
"       not",
"      </strong>",
"      shown benefit. By contrast, prolonged treatment with antibiotics has been associated with a variety of adverse effects (including death) as well as enhancing selection of resistant bacteria. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Lack of benefit from additional antibiotics'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon such observations, the Infectious Diseases Society of America (IDSA) in 2006, the American Academy of Neurology in 2007, and the Ad Hoc International Lyme Disease Group in 2007 concluded that the chronic subjective symptoms that may occur after recommended courses of antibiotic therapy for Lyme disease are not due to persistent infection with B. burgdorferi [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3,47\">",
"     2,3,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reasons for lack of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several reasons for lack of response to standard antibiotic therapy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial diagnosis of Lyme disease was incorrect [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/48-51\">",
"       48-51",
"      </a>",
"      ]. The frequency with which this might occur in the community was illustrated in a review of 209 patients with a presumptive diagnosis of Lyme disease: only 44 (21 percent) met criteria for active Lyme disease, 40 (19 percent) had prior but not active Lyme disease, and 125 (60 percent) had no evidence of current or prior Lyme disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with early Lyme disease may be coinfected with another agent transmitted by Ixodes ticks, such as Babesia spp or Anaplasma phagocytophilum, which cause babesiosis and human granulocytic anaplasmosis, respectively. However, coinfection would",
"      <strong>",
"       not",
"      </strong>",
"      be an explanation for lack of response in patients with late Lyme disease, such as Lyme arthritis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Possible coinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is possible to have both Lyme disease that has been cured and another condition that persists. Examples include fibromyalgia, depression, patellofemoral joint disease, or another clinical entity not related to Lyme disease. Fibromyalgia, in particular, can occur following treatment for Lyme disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical manifestations of Lyme disease in adults\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The knee synovitis of Lyme disease may persist for months after antibiotic therapy possibly due to the triggering of an autoimmune process [",
"      <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with previous neurologic involvement, permanent tissue damage may have occurred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Lack of benefit from additional antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-Lyme disease symptoms are difficult to treat. Randomized controlled trials of repeat antimicrobial therapy in such patients have",
"    <strong>",
"     not",
"    </strong>",
"    shown benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/54-58\">",
"     54-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two parallel multicenter controlled trials were performed of prolonged antibiotic therapy in a total of 129 patients with clinical evidence of Lyme disease and persistent subjective symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/54\">",
"     54",
"    </a>",
"    ]. The symptoms began within six months of the original treatment for acute Lyme disease and lasted for at least six months but less than 12 years by the time of study entry. One trial was conducted in 78 seropositive patients and one in 51 seronegative patients who had clinician observed erythema migrans lesions. Treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily for 30 days) followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg PO twice daily for 60 days) was compared with treatment with placebo (also identically administered IV then orally).",
"   </p>",
"   <p>",
"    The two trials were terminated early after an interim analysis in the first 107 patients showed similar outcomes in the two groups. As an example, improvement in physical and mental component scales was seen in 37 percent of seropositive patients receiving antibiotics and 40 percent receiving placebo, no change in 29 and 26 percent, and worsening in 34 percent in both groups.",
"   </p>",
"   <p>",
"    Another trial included 55 patients with Lyme disease and severe fatigue for at least six months after appropriate antibiotic therapy; the patients were randomly assigned to 28 days of therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/56\">",
"     56",
"    </a>",
"    ]. Treated patients had a modest improvement in fatigue compared with those given placebo, but there was no difference in cognitive function or a laboratory measure of persistent infection. The authors concluded that intravenous therapy was not indicated for post-Lyme disease fatigue symptoms.",
"   </p>",
"   <p>",
"    This was also illustrated in a trial in which 37 patients with post-treatment neurocognitive findings and 20 controls were randomly assigned to 10 weeks of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/57\">",
"     57",
"    </a>",
"    ]. Short-term cognitive improvement was noted at week 12, but was not sustained at week 24 in patients who received ceftriaxone. In addition, 26 percent of those who received ceftriaxone experienced serious adverse effects, most commonly related to the peripherally-inserted central intravenous catheter.",
"   </p>",
"   <p>",
"    Other reports of serious adverse effects in patients receiving prolonged courses of antibiotics for presumed Lyme disease have included anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/56\">",
"     56",
"    </a>",
"    ], severe or fatal catheter-associated bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/56,59\">",
"     56,59",
"    </a>",
"    ], and fatal Clostridium difficile colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recommended approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reevaluation, rather than immediate or reflexive retreatment, is the proper next step in cases of apparent refractory symptoms after a course of appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/51\">",
"     51",
"    </a>",
"    ]. Further antibiotic therapy for Lyme disease should",
"    <strong>",
"     not",
"    </strong>",
"    be given unless there are objective findings of active disease (including physical findings, abnormalities on cerebrospinal or synovial fluid analysis, or changes on formal neuropsychologic testing). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2006 and 2007, Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN) quality standards subcommittee, and the Ad Hoc International Lyme Disease Group separately reviewed the use of additional antibiotic treatment in patients with persistent subjective symptoms after Lyme disease and concluded that additional or prolonged antibiotic treatment beyond the initial treatment course is not effective and is associated with significant adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/2,3,47,61\">",
"     2,3,47,61",
"    </a>",
"    ]. It was recommended that extended courses of antibiotics",
"    <strong>",
"     not",
"    </strong>",
"    be given for presumed \"chronic\" Lyme disease.",
"   </p>",
"   <p>",
"    In contrast to these general recommendations, selected patients with persistent Lyme arthritis may benefit from a second course of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"     \"Musculoskeletal manifestations of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of individuals infected with B. burgdorferi have asymptomatic IgG seroconversion by ELISA and Western blot [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, many patients request testing for Lyme disease, often in the absence of findings to suggest that they are infected.",
"   </p>",
"   <p>",
"    If IgG serologic tests are positive, the question then arises as to whether treatment is warranted. Assuming that a positive ELISA has been corroborated by Western blot analysis (ie, the ELISA is a true positive), a clinical evaluation should be performed to rule out subtle manifestations of Lyme disease. If there are clinical features compatible with Lyme disease, we treat with the regimen most appropriate for those findings.",
"   </p>",
"   <p>",
"    If constitutional symptoms are present, or even if no symptoms are uncovered, we suggest giving a single 28 day course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    to seropositive patients who have not previously received antibiotic therapy for Lyme disease. The main argument for treating asymptomatic seropositive patients is that some patients with late manifestations of Lyme disease have no history of prior features of the disease. Thus, true asymptomatic seropositivity could represent early subclinical infection that may progress to late Lyme disease. It should be noted that some experts would not treat asymptomatic seropositive individuals with antibiotics given that the potential benefit of treatment in such patients has not been established definitively.",
"   </p>",
"   <p>",
"    Even in seropositive patients, constitutional symptoms may not be due to Lyme disease. Therefore, if patients fail to improve after a single 28 day course of oral antibiotics, we would not suggest further antibiotic treatment for Lyme disease.",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend serologic tests for patients who have had tick bites but have no symptoms of Lyme disease, since the incidence of asymptomatic seroconversion following a tick bite is extremely low. Among 869 patients in two randomized controlled trials of chemoprophylaxis in the United States, no asymptomatic seroconversions were detected following tick bites [",
"    <a class=\"abstract\" href=\"UTD.htm?26/54/27498/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"       \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of Lyme disease depends upon the clinical manifestations of the disease as summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Early (erythema migrans)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early disease usually occurs a few days to one month after an Ixodes tick bite and is typically characterized by an erythema migrans skin lesion with or without nonspecific complaints resembling a viral syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Early disease (erythema migrans)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults and children &ge;8 years of age with early Lyme disease, we recommend treatment with one of the following antibiotics:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of antimicrobial agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      be avoided in children &lt;8 years of age with early localized Lyme disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Such children should receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of antimicrobial agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant or lactating women with early Lyme disease, we recommend that the treatment be the same as for nonpregnant patients except that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      should be avoided (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of antimicrobial agent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      for most patients with early localized Lyme disease since it is effective against both Lyme disease and human granulocytic anaplasmosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Choice of antimicrobial agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical duration of therapy for erythema migrans is 10 to 21 days (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 15 percent of patients, particularly those with multiple erythema migrans skin lesions, may experience a transient worsening of symptoms during the first 24 hours of therapy for early Lyme disease, consistent with a Jarisch-Herxheimer reaction. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Jarisch-Herxheimer reaction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Early disseminated",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early disseminated disease occurs weeks to months after the tick bite and may include cardiac, neurologic, and musculoskeletal manifestations. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Early disseminated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with early disseminated disease with isolated facial nerve palsy (in the absence of CSF abnormalities), we recommend oral therapy as for early localized disease (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The typical duration is 14 to 28 days. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Recommended antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have early disseminated disease with meningitis, we recommend IV antibiotic therapy (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The typical duration is 28 days. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Recommended antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with early disseminated disease and carditis who are symptomatic, have second or third degree AV block, or have first degree AV block with a prolonged PR interval (&ge;300 msec) should be admitted to the hospital for monitoring with cardiac telemetry and consideration of a temporary pacemaker. We recommend that all patients who require hospital admission be treated with IV antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      rather than oral antibiotics (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). IV antibiotics should be continued until the heart block has resolved, and the patient may then be switched to oral therapy to complete a 21 to 28 day course (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link&amp;anchor=H10#H10\">",
"       \"Lyme carditis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that asymptomatic patients with early disseminated disease and first-degree AV block with a PR interval &lt;300 milliseconds who are not admitted to the hospital be treated initially with oral therapy (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The total duration of therapy for such patients is 21 days. We suggest that patients who are admitted to the hospital for cardiac monitoring be treated initially with IV antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients should be switched to an oral regimen prior to or at the time of hospital discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link&amp;anchor=H89979907#H89979907\">",
"       \"Lyme carditis\", section on 'Oral therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Late",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late Lyme disease occurs months to years after the tick bite. Arthritis is the major manifestation; neurologic findings also may occur but are rare. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Late disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of Lyme arthritis in the absence of neurologic findings is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link&amp;anchor=H12#H12\">",
"       \"Musculoskeletal manifestations of Lyme disease\", section on 'Management of Lyme arthritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with late Lyme neurologic disease, we recommend intravenous therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The typical duration of therapy is 28 days. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Late neurologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acrodermatitis chronica atrophicans, we suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"UTD.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Doxycycline is avoided in children &lt;8 years of age and pregnant women. The duration of therapy is 21 days. (See",
"      <a class=\"local\" href=\"#H2252074771\">",
"       'Acrodermatitis chronica atrophicans'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Post-Lyme disease symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that extended courses of antibiotics NOT be given for presumed \"chronic\" Lyme disease given the lack of evidence demonstrating benefit and the potential for adverse effects. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Post-Lyme disease syndrome and chronic Lyme disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Asymptomatic seropositivity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic seropositive patients who have not previously received antibiotic therapy for Lyme disease, we suggest giving a single course of oral therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients should receive a single 28 day course of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . Some experts would not treat asymptomatic seropositive individuals with antibiotics given that the potential benefit of treatment in such patients has not been established definitively. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Asymptomatic seropositive individuals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/1\">",
"      Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/2\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/3\">",
"      Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/4\">",
"      Dattwyler RJ, Volkman DJ, Conaty SM, et al. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990; 336:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/5\">",
"      Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/6\">",
"      Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/7\">",
"      Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/8\">",
"      Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983; 99:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/9\">",
"      Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med 1992; 92:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/10\">",
"      Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997; 337:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/11\">",
"      Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000; 28:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/12\">",
"      Terekhova D, Sartakova ML, Wormser GP, et al. Erythromycin resistance in Borrelia burgdorferi. Antimicrob Agents Chemother 2002; 46:3637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/13\">",
"      Hunfeld KP, Kraiczy P, Kekoukh E, et al. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents--possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol 2002; 291 Suppl 33:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/14\">",
"      Nowakowski J, McKenna D, Nadelman RB, et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000; 9:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/15\">",
"      Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992; 36:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/16\">",
"      Stupica D, Lusa L, Ruzi-Sablji E, et al. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis 2012; 55:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/17\">",
"      Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/18\">",
"      Nowakowski J, Nadelman RB, Forseter G, et al. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol 1995; 32:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/19\">",
"      Kowalski TJ, Tata S, Berth W, et al. Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. Clin Infect Dis 2010; 50:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/20\">",
"      Steere AC. Lyme disease. N Engl J Med 1989; 321:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/21\">",
"      Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann Intern Med 1983; 99:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/22\">",
"      Karlsson M, Hammers-Berggren S, Lindquist L, et al. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994; 44:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/23\">",
"      Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999; 28:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/24\">",
"      Pfister HW, Preac-Mursic V, Wilske B, et al. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/25\">",
"      Dattwyler RJ, Wormser GP, Rush TJ, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005; 117:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/26\">",
"      Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/27\">",
"      Pfister HW, Preac-Mursic V, Wilske B, Einh&auml;upl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol 1989; 46:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/28\">",
"      Kohlhepp W, Oschmann P, Mertens HG. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. J Neurol 1989; 236:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/29\">",
"      Lj&oslash;stad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008; 7:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/30\">",
"      Sicklinger M, Wienecke R, Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol 2003; 41:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/31\">",
"      Wormser GP, Halperin JJ. Oral doxycycline for neuroborreliosis. Lancet Neurol 2008; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/32\">",
"      Karlsson M, Hammers S, Nilsson-Ehle I, et al. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 1996; 40:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/33\">",
"      Clark JR, Carlson RD, Sasaki CT, et al. Facial paralysis in Lyme disease. Laryngoscope 1985; 95:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/34\">",
"      Kalish RA, Kaplan RF, Taylor E, et al. Evaluation of study patients with Lyme disease, 10-20-year follow-up. J Infect Dis 2001; 183:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/35\">",
"      Lardieri G, Salvi A, Camerini F, et al. Isolation of Borrelia burgdorferi from myocardium. Lancet 1993; 342:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/36\">",
"      Gasser R, Dusleag J, Reisinger E, et al. Reversal by ceftriaxone of dilated cardiomyopathy Borrelia burgdorferi infection. Lancet 1992; 339:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/37\">",
"      L&oacute;rincz I, Lakos A, Kov&aacute;cs P, et al. Temporary pacing in complete heart block due to Lyme disease: a case report. Pacing Clin Electrophysiol 1989; 12:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/38\">",
"      Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/39\">",
"      Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999; 180:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/40\">",
"      Bloom BJ, Wyckoff PM, Meissner HC, Steere AC. Neurocognitive abnormalities in children after classic manifestations of Lyme disease. Pediatr Infect Dis J 1998; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/41\">",
"      Kindstrand E, Nilsson BY, Hovmark A, et al. Peripheral neuropathy in acrodermatitis chronica atrophicans - effect of treatment. Acta Neurol Scand 2002; 106:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/42\">",
"      Strle F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr 1999; 111:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/43\">",
"      Krause PJ, Foley DT, Burke GS, et al. Reinfection and relapse in early Lyme disease. Am J Trop Med Hyg 2006; 75:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/44\">",
"      Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin Infect Dis 2007; 45:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/45\">",
"      Hunfeld KP, Ruzic-Sabljic E, Norris DE, et al. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 2005; 49:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/46\">",
"      Shadick NA, Phillips CB, Sangha O, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999; 131:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/47\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/48\">",
"      Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/49\">",
"      Reid MC, Schoen RT, Evans J, et al. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/50\">",
"      Qureshi MZ, New D, Zulqarni NJ, Nachman S. Overdiagnosis and overtreatment of Lyme disease in children. Pediatr Infect Dis J 2002; 21:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/51\">",
"      Sigal LH. Persisting complaints attributed to chronic Lyme disease: possible mechanisms and implications for management. Am J Med 1994; 96:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/52\">",
"      Steere AC. Diagnosis and treatment of Lyme arthritis. Med Clin North Am 1997; 81:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/53\">",
"      Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/54\">",
"      Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/55\">",
"      Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003; 60:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/56\">",
"      Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/57\">",
"      Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/58\">",
"      Halperin JJ. Prolonged Lyme disease treatment: enough is enough. Neurology 2008; 70:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/59\">",
"      Patel R, Grogg KL, Edwards WD, et al. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 2000; 31:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/60\">",
"      Holzbauer SM, Kemperman MM, Lynfield R. Death due to community-associated Clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected lyme disease. Clin Infect Dis 2010; 51:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/61\">",
"      Baker PJ. Perspectives on \"chronic Lyme disease\". Am J Med 2008; 121:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/62\">",
"      Steere AC, Sikand VK, Schoen RT, Nowakowski J. Asymptomatic infection with Borrelia burgdorferi. Clin Infect Dis 2003; 37:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/63\">",
"      Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/54/27498/abstract/64\">",
"      Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327:1769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7896 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27498=[""].join("\n");
var outline_f26_54_27498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL STAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROPHYLAXIS FOR TICK BITE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EARLY DISEASE (ERYTHEMA MIGRANS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of antimicrobial agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Possible coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Jarisch-Herxheimer reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EARLY DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Facial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Recommended antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Carditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89981358\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89981365\">",
"      IV therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89981372\">",
"      Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89981379\">",
"      - Telemetry and pacemakers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LATE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Late neurologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2252074771\">",
"      Acrodermatitis chronica atrophicans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2353682622\">",
"      REINFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POST-LYME DISEASE SYNDROME AND CHRONIC LYME DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reasons for lack of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Lack of benefit from additional antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recommended approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Early (erythema migrans)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Early disseminated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Late",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Post-Lyme disease symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Asymptomatic seropositivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7896|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/10/10400\" title=\"picture 1\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7896|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/35/22078\" title=\"table 1\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/7/40060\" title=\"table 2\">",
"      Signs of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39321?source=related_link\">",
"      Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=related_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26552?source=related_link\">",
"      Immunopathogenesis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26533?source=related_link\">",
"      Southern tick-associated rash illness (STARI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=related_link\">",
"      Treatment of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_54_27499="Effect of maternal age and embryos transferred on outcome";
var content_f26_54_27499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effect of maternal age and number of embryos transfered on birth outcome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Maternal age, years",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Three embryos transfered",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Two embryos transfered",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"1\">",
"       Live birth*",
"      </td>",
"      <td class=\"subtitle2\">",
"       Triplet or higher&bull;",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"1\">",
"       Live birth",
"      </td>",
"      <td class=\"subtitle2\">",
"       Triplet or higher",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &lt;35",
"      </td>",
"      <td>",
"       41.6",
"      </td>",
"      <td>",
"       5.6",
"      </td>",
"      <td>",
"       48.6",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       35 to 37",
"      </td>",
"      <td>",
"       39.4",
"      </td>",
"      <td>",
"       3.7",
"      </td>",
"      <td>",
"       39.7",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       38 to 40",
"      </td>",
"      <td>",
"       29.0",
"      </td>",
"      <td>",
"       1.4",
"      </td>",
"      <td>",
"       27.3",
"      </td>",
"      <td>",
"       0.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       41 to 42",
"      </td>",
"      <td>",
"       15.7",
"      </td>",
"      <td colspan=\"1\">",
"       0.4",
"      </td>",
"      <td>",
"       12.0",
"      </td>",
"      <td>",
"       not available",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Percent of live births per IVF transfer procedure.",
"     <br>",
"      &bull; Multiple births per live birth.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Sunderam S, Chang J, Flowers L et al. MMWR Surveill Summ 2009; 58:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27499=[""].join("\n");
var outline_f26_54_27499=null;
var title_f26_54_27500="Drugs for PH";
var content_f26_54_27500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of medications used inthe treatment of pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose range, adult",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epoprostenol*",
"       </td>",
"       <td>",
"        Continuous IV",
"       </td>",
"       <td>",
"        1 to 20 ng/kg/min",
"       </td>",
"       <td>",
"        3 to 5 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treprostinil*",
"       </td>",
"       <td>",
"        Continuous SC/IV",
"       </td>",
"       <td>",
"        0.625 to 1.25 ng/kg/min",
"       </td>",
"       <td>",
"        4 to 5 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iloprost",
"       </td>",
"       <td>",
"        Inhaled",
"       </td>",
"       <td>",
"        2.5 to 5 mcg, 6 to 9 times/day",
"       </td>",
"       <td>",
"        1 to 2 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treprostinil",
"       </td>",
"       <td>",
"        Inhaled",
"       </td>",
"       <td>",
"        6-18 mcg, 4 times daily",
"       </td>",
"       <td>",
"        4 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bosentan",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        62.5 to 125 mg, 2 times/day",
"       </td>",
"       <td>",
"        5 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambrisentan",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        5 to 10 mg/day",
"       </td>",
"       <td>",
"        9 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sildenafil",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        20 mg, 3 times/day",
"       </td>",
"       <td>",
"        4 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tadalafil",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        40 mg/day",
"       </td>",
"       <td>",
"        35 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        30 to 240 mg/day",
"       </td>",
"       <td>",
"        2 to 5 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diltiazem",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        120 to 900 mg/day",
"       </td>",
"       <td>",
"        2 to 4.5 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amlodipine",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        2.5 to 20 mg/day",
"       </td>",
"       <td>",
"        30 to 50 hr",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The dose range shown is for a short-term infusion; higher doses are required for long-term infusions (range often exceeds 100 to 150 ng per kg per minute).",
"     <br>",
"      &bull;&nbsp;The half-life shown refers to immediate-release preparations; however sustained-release preparations that can be administered once daily are available and preferred for maintenance.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27500=[""].join("\n");
var outline_f26_54_27500=null;
var title_f26_54_27501="ICD reduces mortality in patients with LV dysfunction";
var content_f26_54_27501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ICD reduces mortality in patients with left ventricular dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 206px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actuarial survival curves show that, compared to a hypothetical death rate based upon the occurrence of ventricular tachycardia (VT) at a rate &gt;240 beats per min (bpm) identified and stored by the device, the implantable cardioverter defibrillator (ICD) reduced total death, sudden death and fast VT (rate &gt;240 bpm) among patients with a left ventricular ejection fraction &le;30 percent; a similar relationship was noted in those with a history of congestive heart failure (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bocker, D, Bansch, D, Heinecke, A, et al, Circulation 1998; 98:1636.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27501=[""].join("\n");
var outline_f26_54_27501=null;
var title_f26_54_27502="Units solute measurement";
var content_f26_54_27502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Units of solute measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 137px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between various units of measurement. Both NaCl and CaCl2 behave as if they are incompletely dissociated because ionic interactions limit the random movement of activity of the ions. Thus, the mosmol values (1.75 and about 3) are less than predicted from the number of particles (2 and 4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27502=[""].join("\n");
var outline_f26_54_27502=null;
var title_f26_54_27503="Resisting thumb extension";
var content_f26_54_27503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resisting thumb extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The examiner supports the patient's arm with one hand, and asks the patient to extend the thumb against resistance applied by the opposite hand of the examiner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_54_27503=[""].join("\n");
var outline_f26_54_27503=null;
